1	<i>Bifidobacterium longum</i> modifies a nutritional intervention for stunting in Zimbabwean infants
2	Authors: Ethan K Gough ^{1,*} , Thaddeus J Edens ² , Lynnea Carr ³ , Ruairi C Robertson ⁴ , Kuda Mutasa ⁵ , Robert
3	Ntozini⁵, Bernard Chasekwa⁵, Hyun Min Geum⁶, Iman Baharmand⁶, Sandeep K Gill⁶, Batsirai Mutasa⁵,
4	Mduduzi N N Mbuya ^{5,7} , Florence D Majo ⁵ , Naume Tavengwa ⁵ , Freddy Francis ⁸ , Joice Tome ⁵ , Ceri
5	Evans ^{4,5,9} , Margaret Kosek ¹⁰ , Andrew J Prendergast ^{4,5} , Amee R Manges ^{6,11} for the Sanitation Hygiene
6	Infant Nutrition Efficacy (SHINE) Trial Team.
7	Affiliations:
8	¹ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
9	21205, USA.
10	² Devil's Staircase Consulting, West Vancouver, BC, Canada.
11	³ Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, V6T 1Z3,
12	Canada.
13	⁴ Blizard Institute, Queen Mary University of London, London, E1 2AT, UK.
14	⁵ Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
15	⁶ School of Population and Public Health, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
16	⁷ Global Alliance for Improved Nutrition, Washington, DC, 20036, USA.
17	⁸ Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V6T 1Z2, Canada.
18	⁹ Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, L69
19	3BX, UK
20	¹⁰ University of Virginia School of Medicine, Charlottesville, VA, USA.

21	¹¹ British Columbia Centre for Disease Control (BCCDC), Vancouver, BC, Canada.
22	*Correspondence: <u>egough1@jh.edu</u>
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	

40 Summary

41	Child stunting is an indicator of chronic undernutrition and reduced human capital. Small-quantity lipid-
42	based nutrient supplements (SQ-LNS) has been widely tested to reduce stunting, but has modest effects.
43	The infant intestinal microbiome may contribute to stunting, and is partly shaped by mother and infant
44	histo-blood group antigens (HBGA). We investigated whether mother-infant fucosyltransferase status,
45	which governs HBGA, and the infant gut microbiome modified the impact of SQ-LNS on stunting at age
46	18 months among Zimbabwean infants in the SHINE Trial (NCT01824940). We found that mother-infant
47	fucosyltransferase discordance and Bifidobacterium longum modified SQ-LNS efficacy. Infant age-related
48	microbiome shifts in <i>B. longum</i> subspecies dominance from <i>infantis</i> , a proficient human milk
49	oligosaccharide utilizer, to suis or longum, proficient plant-polysaccharide utilizers, were partly
50	influenced by discordance in mother-infant FUT2+/FUT3- phenotype, suggesting that a "younger"
51	microbiome at initiation of SQ-LNS reduces its benefits on stunting in areas with a high prevalence of
52	linear growth restriction.
53	
54	Keywords: microbiome, nutrition, fucoslytransferase, histo-blood group antigen, stunting, infant
55	
56	
57	
58	
59	

61 Introduction

Globally, 21% of children under 5 years of age (149 million) are stunted¹, defined as having a length
 or height >2 standard deviations below an age- and sex-matched reference population median². Deficits
 in linear growth largely accrue from conception to 24 months of age^{3,4}, corresponding to the period
 when normal child growth and development is most rapid. Stunting is associated with reductions in child
 survival, neurodevelopment, educational attainment, and adult economic productivity⁵⁻⁷.

67 A broadly tested intervention to reduce stunting has been provision of small-quantity lipid-based nutrient supplements (SQ-LNS) to improve infant and young child feeding (IYCF) starting at 6-months 68 69 (mo) of age, which is the recommended time for introduction of complementary foods. Randomized 70 controlled trials (RCT) of SQ-LNS provision to infants have shown small reductions in stunting (12% relative reduction), but effects have varied^{8,9}. Evidence to support other nutrition interventions, which 71 address the underlying determinants of stunting during the first 1000 days of life, starting from 72 conception, is also limited¹⁰. Elucidating the reasons for the limited impact of nutritional interventions 73 74 that are designed to alleviate stunting is crucial to the development of more effective strategies. Recently, the human microbiome has been shown to impact infant health¹¹, and studies suggest a 75 role of the intestinal microbiome in child growth, particularly ponderal growth^{12,13}. The prevailing view 76 77 holds that intestinal colonization with bacteria begins at birth, after which the microbiome progresses through a succession of identifiable shifts in composition and functional capacity¹¹ that correspond 78 closely with infant age and developmental stage¹⁴. Deviations from an age-appropriate composition may 79 be associated with poor health outcomes^{14–17}, including undernutrition in low resource settings^{14,18–20}. 80 However, results vary²¹⁻²⁵ and evidence for a causal effect of the intestinal microbiome on growth 81 82 comes predominantly from animal models. In these experiments, a combination of commensal bacteria 83 and a nutrient-poor diet produce a synergistic effect on growth faltering. The detrimental effect on

84 growth was worse when certain commensal bacteria, which can act as pathobionts (e.g. Bacteroides thetaiotaomicron and Bacteroides fragilis), were present in the gut along with pathogenic species^{26,27}. 85 86 The gut microbiome in infants is influenced by breastfeeding, with differences persisting beyond age 6mo¹⁶. Breastfeeding-associated differences are partly driven by differences in human milk 87 88 oligosaccharide (HMO) composition, which are metabolized by specific commensal bacteria and thereby influence the growth and activity of bacterial populations in the infant gut, in particular, 89 Bifidobacterium^{28,29}. In addition, HMOs in combination with commensal gut bacteria have been shown 90 to improve growth in animal models of undernutrition³⁰. Active maternal α -1,2-fucosyltransferase 91 (FUT2) and α -1,3-fucosyltransferase (FUT3) genes are key determinants of HMO composition^{31–33}. These 92 93 genes encode enzymes which catalyze addition of fucose to the disaccharides that serve as precursors to host glycan production^{34,35}. Individuals with at least one functional FUT2 or FUT3 allele produce 94 95 fucosylated histo-blood group antigens (HBGA) and are called "secretors" or "Lewis-positive", respectively;³⁵ by contrast, individuals lacking two functional FUT2 or FUT3 alleles don't produce 96 97 fucosylated HBGAs, and are termed "non-secretors" or "Lewis-null", respectively³⁵. These secretor and Lewis phenotypes act in concert to synthesize a variety of HBGAs (Figure S1)^{34,35}. In addition to the 98 99 impact of maternal FUT2 or FUT3 status on the infant gut microbiome via their influence on HMO 100 composition, host FUT2 and FUT3 phenotypes also determine tissue surface HBGA expression in the gut, 101 which may also affect the microbiome through the availability host glycans and competition for adhesion sites^{36–40}. 102 103 There is growing interest in the moderating effect of the gut microbiome on nutritional 104 interventions. Recent RCTs showed that the impact of dietary interventions for weight reduction on metabolic health outcomes is modified up to 4-fold by microbiota composition⁴¹⁻⁴⁴. Effect modification 105

106 of host diet by the gut microbiota has also been investigated in observational studies, which report that

107 microbiome composition modified the association between diet and biomarkers of metabolic syndrome

by up to 2-fold^{45–47}. Gut microbiota composition, therefore, may also be an important modifier of dietary
interventions on infant health. Only one study to date investigated the gut microbiota as an effect
modifier of SQ-LNS on infant stunting, and reported limited evidence of effect-modification⁴⁸. However,
several studies have reported a synergistic effect of microbiome composition and diet on undernutrition
phenotypes using animal models^{26,27,49,50}.

113 Here we aimed to determine the effect of infant gut microbiome composition and functional 114 capacity on efficacy of an IYCF intervention that included SQ-LNS to reduce stunting (primary outcome) 115 and improve length-for-age z-score (LAZ) (secondary outcome) at age 18mo. We hypothesized that the 116 efficacy of IYCF, when started at age 6mo, on infant linear growth is modified by mother and infant FUT2 117 and FUT3 phenotype, as an drivers of variation in gut microbiome composition, and by the infant gut 118 microbiome. We tested this hypothesis using data from HIV-unexposed infants enrolled in the Sanitation 119 Hygiene Infant Nutrition Efficacy (SHINE) trial conducted in rural Zimbabwe, in which the IYCF 120 intervention modestly increased LAZ by 0.16 standard deviations and reduced stunting by 20% at age 18mo⁵¹. We found that mother-infant FUT2 and FUT3 phenotype, where the mother was FUT2+/FUT3-121 122 but the infant was not, was associated with greater IYCF reduction of stunting at 18mo. Greater impact 123 of IYCF on stunting was also associated with infant microbiome species maturation, characterized by a 124 shift away from *Bifidobacterium longum* carriage. *B. longum*-dominant microbiome composition was 125 characterized by B. longum strains that were most similar to subspecies infantis, a proficient HMO 126 utilizer. In addition, B. longum abundance and odds of detecting different B. longum strains were 127 explained by infant age and differences between mother-infant pairs in FUT2+/FUT3- phenotype. 128

129

130

132 Results

133 Mother-infant FUT2+/FUT3- phenotype discordance modifies the effect of IYCF on stunting at 18mo 134 In a substudy of the SHINE trial, we assessed FUT2 and FUT3 status in mothers and infants from 135 saliva samples. To determine the impact of maternal and infant HBGA on IYCF efficacy, we investigated 136 whether concordance in secretor (FUT2) and Lewis (FUT3) phenotypes between mother and infant pairs 137 modified the effect of IYCF on stunting or LAZ at 18mo. We defined these paired mother-infant 138 phenotypes using combinations of FUT2 and FUT3 status (as presented in Table S1) to more precisely 139 reflect the potential for joint activity of these enzymes in HBGA production (as presented in Figure S1). 140 Each of these paired mother-infant FUT2/FUT3 phenotypes were classified as both (if mother and infant 141 shared the same phenotype), none (if neither had the phenotype), infant only (if the infant had the 142 phenotype but the mother did not) or *mother only* (if the infant did not have the phenotype but the 143 mother did). We fitted multivariable regression models that included terms for the interaction of IYCF 144 and each paired FUT2/FUT3 phenotype between mother and infant, as well as prespecified covariates 145 from the 6mo follow-up visit when IYCF was started, with stunting status at the 18mo visit as the 146 dependent variable. We fitted separate models for each combination of paired mother-infant 147 FUT2/FUT3 phenotype presented in Table S1 and Figure S1. These models were restricted to 792 infants 148 who had both maternal and infant FUT2 and FUT3 status ascertained (Figure S2). Analyses were 149 repeated with LAZ at the 18mo visit as the dependent variable. 150 Amongst infants who were randomized to IYCF, those who were in the *mother only* FUT2+/FUT3-151 group (13.5%) had a probability of stunting at 18mo that was -33.0% lower (95%CI:-55.0%,-10.0%) than 152 infants in the both FUT2+/FUT3- group (11.1%) (Table 1). The infant only (11.1%) and none (64.3%) 153 FUT2+/FUT3- groups, and other mother-infant FUT2 and FUT3 phenotype combinations (Table S1, 154 Figure S1), did not show evidence of effect modification of IYCF on stunting (Table S2), and there was no 155 evidence of effect modification on LAZ at 18mo after FDR-adjustment for multiple testing (Table S3).

156 Overall, our results indicate that discordance between mothers and infants in the FUT2+/FUT3-

phenotype, whereby mothers had the phenotype and infants didn't have the phenotype, was associated
with increased efficacy of IYCF to reduce stunting but not to increase LAZ.

159

160 Infant gut microbiome composition modifies the effect of the IYCF intervention on stunting at 18mo 161 Given our finding that infants whose mothers were FUT2+/FUT3-, while the infant was not, had 162 greater reductions in stunting by IYCF; and considering the potential importance of FUT2/FUT3 163 phenotypes on early infant microbiome composition via variation in maternal HMO composition and 164 infant gut epithelial HBGA expression, we investigated whether infant gut microbiota species maturation 165 showed evidence for modification of IYCF efficacy on stunting or LAZ at 18mo. First, we used 354 infant 166 metagenomes from 172 infants collected from 1-18mo of age to fit a constrained Principal Coordinates 167 Analysis (PCoA) model that included infant age at stool collection and three dummy variables for 168 mother-infant FUT2+/FUT3- status representing the none, infant only, and mother only groups with the 169 both group as the referent (see next section for details). Thus, we derived four PCoA axis scores from 170 this model representing variation in microbiome composition due to infant age and explained by none, 171 infant only, or mother only FUT2+/FUT3- status compared to both. Next, we fitted a multivariable 172 regression model that included an IYCF-by-PCoA axis 1 score interaction term and prespecified 173 covariates. The regression model was restricted to 53 infants who had a fecal specimen collected at the 174 6mo follow-up visit when IYCF started and used their covariate values at the 6mo visit (Figure S2). 175 Stunting status at 18mo was used as the dependent variable. We repeated our analyses using PCoA axis 176 2 to 4 scores. Finally, we fitted regression models replacing stunting status with LAZ at 18mo as the 177 dependent variable.

Greater PCoA axis 1 scores represented species turnover with increasing infant age (Figure S3), thus
 reflecting microbiota maturation, while greater PCoA axis 2 scores represented changes in species

180 composition associated with mother-infant FUT2+/FUT3- phenotypes (Figure S3). PCoA axis 1 and 2 181 scores showed evidence of interaction with IYCF on stunting at 18mo (Table 2), but not LAZ (Table S4). 182 Amongst infants randomized to IYCF, those with higher PCoA axis 1 scores at age 6mo were less likely to 183 be stunted at 18mo compared to infants with lower PCoA axis 1 scores (difference-in-differences -76.0% 184 [95%CI: -99.0%, -32.0%, adjusted p=0.003) (Table 2). In contrast, infants randomized to IYCF with higher 185 PCoA axis 2 scores at age 6mo were more likely to be stunted at 18mo compared to infants who had 186 lower PCoA axis 2 scores (difference-in-differences, 14.0% [95%CI: 7.0%, 21.0%], adjusted p=0.001) 187 (Table 2). Taken together, our findings showed that infant age-related microbiome species maturation 188 was associated with greater reduction in the probability of stunting at 18mo by IYCF, indicating greater 189 efficacy of the intervention; while microbiome species composition related to mother-infant 190 FUT2+/FUT3- phenotype was associated with lesser reduction in stunting, suggesting variation in 191 microbiome composition due to these infant characteristics is an important determinant of SQ-LNS 192 efficacy to reduce stunting.

193

194 Infant age and mother-infant FUT2+/FUT3- phenotype explain shifts in microbiome species composition,
 195 in particular, Bifidobacterium longum

196 To investigate sources of variation in infant intestinal microbiome composition and derive 197 interpretable measures of species turnover, we performed constrained PCoA of Bray-Curtis 198 dissimilarities with permutational analysis of variance using distance matrices for hypothesis testing. 199 Infant age at stool collection explained 12.6% (ADONIS2 p=0.001) of the variability in microbiome 200 composition (Table S5). Notably, exclusive breastfeeding (EBF) at 3mo was not significantly associated 201 $(R^2$ =0.346, ADONIS2 p=0.483) with microbiome composition (Table S5). However, 93.2% of mothers in 202 these analyses reported exclusive breastfeeding (Table S6). Thus, there may not have been sufficient 203 variability in infant breastfeeding practices in this cohort to identify EBF-associated differences between infant microbiomes. Also, inclusion of specimens collected throughout the follow-up period in our PCoA
 models may have obscured associations with EBF, since EBF is only recommended up to age 6mo.

206 We then fitted a fully adjusted multivariable constrained PCoA model that included both infant age 207 at stool collection and mother-infant FUT2+/FUT3- phenotype. We retained the latter variable to 208 capture variation in microbiota composition associated with mother-infant FUT2+/FUT3- status after 209 controlling for infant age, because of our a priori aim to investigate whether microbiome variation due 210 to mother and infant FUT2/FUT3 phenotype was a modifier of the IYCF intervention, and our finding 211 that the mother only FUT2+/FUT3- group was associated with a modified intervention effect. In the full 212 model, age explained 12.8% (ADONIS p=0.001) and mother-infant FUT2+/FUT3- phenotype explained 213 0.81% (ADONIS p=0.323) of the variation in microbiome composition (Table S5), indicating that infant 214 age was the main driver of microbiome-wide changes in species composition in this cohort.

Age-related maturation in species composition were characterized by decreased relative abundance of *B. longum*, and increased relative abundance of *Prevotella copri*, *Faecalibacterium prausnitzii*, *Dorea longicatena*, and *Dorea formicigenerans* (Figure S4). Mother-infant FUT2+/FUT3- discordance was characterized by increased relative abundance of *B. longum* in the *none* and *infant only* groups (Figure S5-S7).

In combination with our IYCF-by-PCoA effect modification models (see previous section), these
findings indicate that infant microbiota species maturation characterized by a shift away from a
microbiome dominated by *B. longum* (i.e. greater PCoA axis 1 score) was associated with a reduction in
the probability of stunting at age 18mo in infants randomized to IYCF (Table 2). In contrast, species
composition associated with mother-infant FUT2+/FUT3- phenotype (i.e. greater PCoA axis 2 score),
which was characterized by higher *B. longum* abundance, showed evidence of reduced impact of IYCF on
stunting (Table 2).

228 Bifidobacterium longum relative abundance modifies the effect of the IYCF intervention on stunting at 229 18mo

230 To determine if differences in the relative abundances of specific microbiome species that 231 characterized the constrained PCoA axes were also associated with significant modification of IYCF on 232 stunting or LAZ at 18mo, we fitted multivariable regression models that included IYCF-by-species relative 233 abundance interaction terms and prespecified covariates as described in the previous sections. These 234 models were restricted to 53 infants who had a fecal specimen collected at the 6mo follow-up visit 235 when IYCF started and used their covariate values at that visit (Figure S2). We fitted a separate model 236 for each microbiome species of interest, defined as those strongly associated with PCoA axis 1 to 4 237 scores (i.e. loadings > 0.5 or < -0.5). Infants randomized to IYCF who had greater relative abundance of 238 B. longum when the intervention started were more likely to be stunted at age 18mo compared to 239 infants with lower relative abundance of *B. longum* (differences-in-differences 50.0% [95%CI: 240 26.0%,74.0%], adjusted p<0.001) (Table 3). No other species-level interactions with IYCF on stunting 241 were identified (Table 3). Infants randomized to IYCF with greater B. longum relative abundance also 242 had smaller LAZ at 18mo compared to infants with lower *B. longum* abundance; however, this 243 association was not statistically significant after FDR-adjustment (differences-in-differences -0.88[95%CI: 244 -1.45,-0.31], adjusted p=0.074) (Table S7). Overall, our findings indicate that greater relative abundance 245 of B. longum in the infant gut microbiome at initiation of the IYCF intervention was associated with less 246 efficacy of the IYCF intervention to reduce stunting at age 18mo.

247

248 Infants randomized to IYCF in the mother only FUT2+/FUT3- group or with lower B. longum relative

249 abundance were spared from more severe growth faltering

250 To investigate whether these reductions in IYCF efficacy were due to differences in the degree or

timing of growth faltering, we plotted (i) LAZ growth trajectories and (ii) LAZ velocities (sd/mo) from 6-

18mo of age, by both IYCF arm and paired mother-infant FUT2+/FUT3- phenotype. Infants randomized to IYCF in the *mother only* group had a less steep decline in LAZ trajectories on average compared to infants in the *mother only* group randomized to no IYCF (Figure 1). In addition, although all groups of infants had negative 6-18mo LAZ velocities on average, infants in the *mother only* group who were randomized to IYCF had higher LAZ velocity (-0.02 sd/mo,95%CI[-0.05,0.00]) compared to those in the no IYCF group (-0.08 sd/mo, 95%CI[-0.11,-0.05]) (Figure 1). Importantly, infants in the *mother only* group also benefitted more from the IYCF intervention in our interaction models (Table 1).

259 We repeated these exploratory analyses to compare LAZ trajectories and LAZ velocities by both IYCF 260 arm and B. longum at the 6mo visit stratified above or below the relative abundance median. Infants randomized to IYCF who were above the median relative abundance of *B. longum* had declining growth 261 262 trajectories on average, while infants below the median did not (Figure 2). Furthermore, the mean 6-263 18mo LAZ velocity was negative in both *B. longum* groups, but trended toward being higher in the group 264 with relative abundance below (-0.02 sd/mo,95%Cl[-0.07,0.03]) compared to above (-0.08 sd/mo 265 95%CI[-0.12,-0.03]) the median; however, the 95% confidence intervals overlapped. In contrast, among 266 infants randomized to no IYCF, both those with a relative abundance above and those with a relative 267 abundance below the median at the 6mo visit had declining growth trajectories (Figure 2) with similar 268 average negative LAZ velocities (Figure 2).

Overall, these results indicate that the differences in IYCF efficacy by mother-infant FUT2+/FUT3phenotype and *B. longum* relative abundance can be explained by differences in LAZ velocity. Infants in the *mother only* FUT2+/FUT3- group and infants with lower *B. longum* relative abundance at 6mo were spared from more severe LAZ declines, which contributed to a lower probability of stunting at 18mo, even when the differences in velocity were not statistically significant.

Bifidobacterium longum strains most similar to subspecies infantis dominate the early infant gut
microbiome

277 Next, we aimed to identify whether infants carried different strains of *B. longum* using a pangenome approach. We used PanPhlan3.0⁵² to generate UniProt gene family profiles of dominant *B. longum* 278 279 strains from 218 infant gut metagenomes, generated from 136 infant, with sufficient coverage of B. 280 longum (Figure S2). To assess similarities between SHINE B. longum strains and previously characterized 281 subspecies, we also included UniProt gene family profiles produced by PanPhlan for 118 reference 282 strains. We performed PCoA using Jaccard dissimilarities calculated from these gene family presence or 283 absence profiles. Three clusters of B. longum strains were identifiable by visualization of ordination plots 284 (Figure 3 and S8). We, therefore, performed hierarchical clustering of these Jaccard dissimilarities to 285 delineate three distinct strain clusters and place each strain into the most appropriate cluster (Figure 286 S8). Subspecies infantis reference strains predominantly grouped with the largest cluster (hereafter 287 called the infantis cluster) and included 15 infantis reference strains and 255 SHINE strains (Figure 3). 288 Subspecies longum reference strains predominantly grouped with the second largest cluster (longum 289 cluster), including 29 longum, 3 infantis, 64 unclassified subspecies strains and 14 SHINE strains. The 290 remaining cluster included two subspecies suis, one subspecies longum, 4 unclassified subspecies 291 reference strains and 15 SHINE strains (*suis* cluster) (Figure 3 and Figure S8).

292

Infant gut microbiome maturation undergoes a transition in which Bifidobacterium longum strains most
 similar to subspecies infantis become less prevalent

To investigate predictors of *B. longum* relative abundance in infants over time, we fitted a longitudinal multivariable zero-inflated mixed-effects model, using 225 specimens from 87 infants with prespecified covariate data. Covariates included infant age at specimen collection, sex, EBF at 3mo, minimum infant dietary diversity at specimen collection, and mother-infant FUT2+/FUT3- phenotypes (Figure S2). Infant age and mother-infant FUT2+/FUT3- phenotype were significant predictors of *B*. *longum* relative abundance. Each one month increase in infant age was associated with a 0.91-fold
decrease (95%CI:0.90,0.92, p<0.001) in *B. longum*, and the *mother only* FUT2+/FUT3- group had the
lowest relative abundance of *B. longum* throughout follow-up (Figure S11) with a 0.71-fold decrease in
relative abundance (95%CI:0.59,0.87, p=0.001) relative to the *both* group (Table S9).

304 Also, to determine predictors of *B. longum* strain cluster detection in infants over time, we fitted 305 multivariable longitudinal logistic regression models using 133 specimens from 70 infants with 306 PanPhlan3.0 output and prespecified covariate data (Figure S2). We fitted a separate model for each 307 strain to estimate its probability of detection. Results were consistent with predictors of *B. longum* 308 relative abundance. Each one month increase in infant age was associated with a 0.85-fold decreased 309 odds (95%CI:0.75,0.96, p=0.008) of the *infantis* cluster (Table S10). At the same time, the suis and 310 longum clusters increased with age (Table S10 & Figure S12). Female infants had 8.35-fold increased 311 odds of the infantis cluster (95%CI:3.17,21.97, p<0.001); and the infant only FUT2+/FUT3- group, which 312 had the highest probability of the infantis cluster throughout follow-up (Figure S13A), had a 4.66-fold 313 increased odds (95%CI:1.05,20.71, p=0.043) of the *infantis* cluster (Table S10). In contrast, the *mother* 314 only FUT2+/FUT3- group had low probability of carrying an infantis cluster strain (Figure S13A & Table 315 S10) and the highest probability of carrying a *suis* cluster strain (Figure S13C).

In summary, *B. longum* decreased with infant age and was lowest among infants in the *mother only* FUT2+/FUT3- group. The *infantis* cluster, which included the dominant *B. longum* strains, also decreased with infant age. Furthermore, *infantis* cluster strains were most likely to be detected in the *infant only* group, and were less likely to be detected in the *mother only* group, among whom *suis* cluster strains were more likely to be detected. Infant age and mother-infant FUT2+/FUT3- phenotype were important determinants of both *B. longum* relative abundance and strain carriage.

323 Bifidobacterium longum strains most similar to subspecies infantis were characterized by greater

324 capacity for HMO degradation, uptake, siderophore and antimicrobial biosynthesis

325 To identify differences in metabolic potential between *B. longum* strain clusters, we used two-sided 326 Fisher's Exact tests to compare UniProt gene family presence between clusters. We restricted these 327 analyses to the 284 SHINE Bifidobacterium pangenomes to make inferences about differences in metabolic potential between SHINE strains. We then performed overrepresentation analyses⁵³ of 328 329 differentially frequent gene families by one-sided Fisher's Exact test to determine whether they were more likely to be involved in specific GO biological processes⁵⁴, or to function as specific carbohydrate-330 active enzymes (CAZymes)⁵⁵ or transporters⁵⁶. Gene families that were more common in the *infantis* 331 332 cluster were more likely to be involved in HMO degradation, and included genes that function as 333 CAZyme Glycoside Hydrolase Family 20 (GH20) (β -N-acetylglucosaminidases, β -N-334 acetylgalactosamindase, β -6-SO3-N-acetylglucosaminidases, and lacto-N-biosidases), GH29 335 (fucosidases), GH95 (fucosidases), and GH33 (sialidases) (Figure 4A, Table S8). Conversely, gene families 336 that were more common in the other clusters were more likely to be involved in degradation of plant-337 derived polysaccharides, including genes that function as GH42 (β -galactosidases), GH51 (L-338 arabinfuranosidases) and GH127 (β -L-arabinofuranosidase) CAZymes (Figure 4A, Table S8). Similarly, 339 gene families that were more common in the *infantis* cluster were more likely to function as 340 transporters involved in oligosaccharide uptake (TCID 3.A.1.1.59), while those that were less common in 341 the infantis cluster were more likely to be involved in uptake of fructose and other sugars (TCID 342 3.A.1.2.23) (Figure 4A, Table S8). Other differences between strain clusters included greater carriage of 343 gene families among infantis cluster strains that are involved in riboflavin biosynthesis, signal 344 transduction, amino acid catabolism and uptake. We also identified differences between strain clusters in the frequency of 115 MetaCyc⁵⁷ pathways 345

346 identified using MinPath⁵⁸ (Figure S10). Pathways that were more common in the *infantis* cluster were

347 more likely to be involved in generation of precursor metabolites and energy, and secondary metabolite 348 biosynthesis (which predominantly included pathways for biosynthesis of siderophores and 349 antimicrobials) (Figure 4B, Table S8). Conversely, the *infantis* cluster was less likely to include pathways 350 involved in glycan metabolism and polymeric compound degradation (e.g. pectin, xylan, and 351 arabinogalactan degradation pathways), and in fatty acid and lipid biosynthesis (Figure 4B, Table S8). 352 Overall, infant gut microbiomes were dominated by *B. longum* strains that were most similar to 353 subspecies *infantis* in their UniProt gene family profiles. The primary distinction of *B. longum* strains in 354 the infantis cluster was greater capacity for HMO degradation and uptake of oligosaccharides than 355 plant-derived polysaccharides. However, strains in the *infantis* cluster also had greater capacity for 356 siderophore and antimicrobial production, and displayed differences in their capacity for riboflavin, fatty 357 acid, and lipid metabolism.

358

359 Discussion

360 In this study of HIV-unexposed infants enrolled in the SHINE trial in rural Zimbabwe, we tested the 361 hypothesis that mother-infant FUT2/FUT3 phenotype and infant gut microbiome modify the effect of an 362 intervention containing small-quantity lipid based nutrient supplements, on infant stunting and LAZ at 363 18mo of age. Our goal was to define mechanisms that explain the rather modest effects of SQ-LNS on 364 linear growth, reasoning that maternal-infant HBGA phenotypes might be important given their 365 combined role in shaping the early-life microbiome. We found the following features are associated with 366 greater reduction in stunting at 18mo by IYCF: (i) discordance in mother-infant FUT2+/FUT3- phenotype, 367 where the mother has the phenotype but the infant does not; (ii) changes in microbiome species 368 composition that reflected a shift from a *B. longum*-dominant microbiome to a microbiome with less *B*. 369 longum and a greater abundance of species characteristic of older infants; and (iii) decreased B. longum 370 abundance that was associated with paired mother-infant FUT+/FUT3- status. These findings suggest

that a persistently "younger" microbiome, characterized by a high abundance of *B. longum* and carriage
of *B. longum* strains best suited to HMO metabolism, at the point when complementary foods are
introduced into the infant diet, may modify the effects of an intervention that includes SQ-LNS on infant
stunting.

375 The mother only FUT2+/FUT3- group showed evidence of a greater reduction in stunting following 376 receipt of one year of the IYCF intervention. Mother-infant FUT2+/FUT3- phenotype was also a 377 significant predictor of B. longum, whereby relative abundance was lower throughout follow-up in the mother only group. Active maternal FUT2/FUT3 genes are key determinants of milk oligosaccharide 378 composition^{31–33}. Human milk specimens form distinct groups based on maternal FUT2⁵⁹ and FUT3 379 phenotype^{31,33} by principal component analyses of oligosaccharide composition. In particular, 380 381 FUT2+/FUT3- mothers are a subset of FUT2+ women who form an HMO cluster that is distinct from mothers with other phenotypes, including FUT2+ mothers who are also FUT3+^{31,33}. Differences in HMO 382 383 composition influence growth and activity of Bifidobacterium populations in the infant gut^{28,59}. Host 384 FUT2 status may also affect infant gut microbiome composition^{36–40}. Gut Bifidobacterium³⁹, Bacteroides^{36,38}, Faecalibacterium⁴⁰ and Roseburia⁴⁰ are differentially abundant in FUT2+ compared to 385 386 FUT2- individuals. However, reported differences in microbiome composition by FUT2/FUT3 status have 387 been inconsistent, potentially due to variability in age, dietary patterns, host health, sampled gut sections and methodology between studies^{60,614}, and studies predominantly included adults. However, 388 CAZymes found in *B. longum* species that function in HMO degradation (GH29 and GH95) have also been 389 found to function in host intestinal glycan degradation in infants⁶². The evidence, therefore, suggests 390 391 that the FUT2/FUT3 phenotypes of mother and infant, together, can elicit a strong prebiotic selective pressure, driven by maternal milk and infant glycan composition²⁸ that influences Bifidobacteria and 392 393 broader gut microbiota composition in infants.

394 In contrast to our finding that mother-infant FUT2+/FUT3- phenotype predicted the presence of B. 395 longum subspecies infantis cluster strains, a prior study reported that maternal or infant FUT2 or FUT3 status did not predict the abundance of subspecies *infantis* or *longum* in children⁶³. However, we 396 included infant age as a covariate in our models, while the prior study did not⁶³. In addition, to 397 398 accommodate the fact that FUT2 and FUT3 work in concert biologically to produce different HBGAs and 399 HMOs (Figure S1), we defined combined FUT2 and FUT3 phenotypes. Another smaller study found 400 infants born to FUT2+/FUT3- mothers had lower bifidobacterial operational taxonomic unit diversity compared to other infants³⁹. This study provides additional evidence that maternal FUT2+/FUT3-401 402 phenotype is associated with bifidobacterial taxon composition in the infant gut. Furthermore, we considered paired maternal and infant phenotypes⁶³. More research is needed to clarify the roles of 403 404 mother-infant FUT2/FUT3, maternal HMOs and the infant glycobiome as drivers of infant gut 405 microbiome composition and development.

406 In our PCoA model, infant microbiome species maturation predominantly reflected decreased 407 abundance of B. longum and increased abundance of P. copri, F. prausnitzii, D. longicatena, and D. 408 formicigenerans. These species were also important predictors of infant age in a microbiome-age model previously developed from this same cohort⁶⁴. Age-discriminatory taxa in the same genera were also 409 identified in previously reported microbiome-age models¹⁴. Delayed gut microbiota-age has been 410 411 reported in children with severe acute malnutrition (SAM), while improvements in microbiota-age and relative abundance of age-discriminatory taxa have been correlated with better growth¹⁴. Our analyses 412 413 complement this literature with evidence that infant gut microbiome species maturation increased the 414 effect of the IYCF intervention on stunting at 18mo, while greater relative abundance of B. longum, an 415 age-discriminatory taxon which is associated with younger age, reduced the effect. This suggests that 416 delayed maturation of the gut microbiome at the point when complementary foods are introduced and 417 IYCF is initiated, may impair IYCF-induced effects on growth.

Infant age was the strongest determinant of *B. longum* relative abundance over time. This is
consistent with previous reports⁶⁵. In breastfed infants, Bifidobacteria are the most abundant gut
bacteria^{65,66}. Human breast milk is rich in oligosaccharides, which Bifidobacteria preferentially utilize⁶⁷.
At introduction of solid foods, a wider variety of nutrients and reduced availability of HMOs correspond
to a decrease in Bifidobacterium,⁶⁸ greater bacterial diversity and evenness, and development of a more
adult-like composition by 2–3 years of age^{11,69–71}.

Utilization of HMOs by Bifidobacterium varies between species and strains^{72–78}. We identified three 424 425 clusters of dominant B. longum strains that also varied by infant age and mother-infant FUT2+/FUT3-426 phenotype. The cluster of strains with pangenomes most closely resembling subspecies infantis had the 427 highest prevalence in early infancy. However, by age 18mo there was a marked decrease in detection of 428 infantis cluster strains and a corresponding increase in detection of strains with pangenomes most 429 similar to subspecies suis, which had the highest prevalence at 18mo. Strains most similar to subspecies 430 longum increased more slowly. This finding is consistent with a recent study that also reported a pattern 431 of succession among three distinct gut B. longum clades from birth to 24mo of age. Subspecies infantis 432 was dominant in early infancy but peaked at age 6mo and decreased considerably thereafter. While a 433 transitional clade that included strains most similar to subspecies suis and suillum showed a 434 corresponding increase in abundance that peaked by 18mo, and subspecies *longum* expanded from 15mo-24mo of age⁷⁹. In that report, the transitional *suis/suillum* clade harbored functional capacity to 435 436 degrade both HMOs and dietary polysaccharides, suggesting it may be an adaptation of the infant gut 437 microbiome to a period when breastfeeding may co-occur with introduction of complementary foods⁷⁹. 438 We add to this work by showing that differences between mother and infant in FUT2+/FUT3- phenotype 439 may also play a role in driving this transition, whereby, throughout follow-up, the mother only 440 FUT2+/FUT3- group had a low prevalence of the *infantis* cluster and the highest prevalence of the *suis* 441 cluster; while the *infantis* cluster was most prevalent in the *infant only* group.

B. longum subspecies infantis are particularly well adapted for HMO utilization^{80,81}. B. longum 442 443 subspecies longum, on the other hand, do not grow as well on HMO, and are more specialized for utilization of diet-derived polysaccharides⁸². In our analyses, UniProt gene families that were more 444 445 frequent in the infantis cluster were more likely to be involved in HMO degradation and uptake. Two of CAZyme families more likely to be carried by the *infantis* cluster (GH29⁸³ and GH33⁷⁴) were previously 446 447 reported as more prevalent in subspecies infantis strains. In contrast, UniProt gene families that were 448 less frequent in the *infantis* cluster were more likely to be involved in uptake of fructose and other 449 simple sugars, including the sugar transporter 3.A.1.2.23, which was previously described in a different B. longum subspecies⁸⁴. Furthermore, strains in the suis and longum clusters were more likely to carry 450 451 UniProt gene families involved in such MetaCyc pathways as pectin, xylan, and arabinogalactan 452 degradation. UniProt gene families found more frequently in *infantis* cluster strains were also more 453 likely to be involved in siderophore and antimicrobial biosynthesis. Heavy metals such as iron and zinc 454 are essential minerals for nearly all bacteria and their mammalian hosts. Strategies utilized by bacteria 455 to acquire heavy metals include siderophore biosynthesis. Siderophores are low molecular weight iron-456 chelating compounds that are synthesized by bacteria to scavenge iron and other essential metals such as zinc under nutrient-restricted conditions⁸⁵. For example, Bifidobacterium species isolated from iron-457 deficient children efficiently sequester iron via siderophore production⁸⁶. Siderophores may provide a 458 competitive advantage to Bifidobacteria⁸⁷, which along with antimicrobial biosynthesis⁸⁸, may also help 459 protect the infant gut from enteric pathogens that require essential metals for colonization. However, 460 essential metals such as iron and zinc are key components in SQ-LNS formulations⁸⁹⁻⁹¹, and produce 461 improvements in linear growth and reductions in stunting risk^{92,936}. While siderophore activity varies 462 463 considerably between Bifidobacterium species and strains, no research to date has investigated 464 sequestration of essential metals by subspecies infantis strains commonly found in resource-limited 465 settings. Overall, our analyses suggest that greater abundance of B. longum, at the time when IYCF is

started, characterized by a predominance of strains with carriage of gene families which confer greater
capacity for HMO utilization and siderophore biosynthesis, is associated with lower impact to reduce
stunting at 18mo. These suggest potential mechanisms by which a "younger" microbiome may constrain
the beneficial effects of an SQ-LNS intervention on infant stunting. However, more research is required
to fully elucidate the biological mechanisms and downstream pathways to stunting that could be
involved.

472 Our results are in contrast to a previous RCT that investigated infant microbiome composition as a modifier of SQ-LNS impact on infant growth In Malawi⁴⁸. However, in the primary analyses of that RCT, 473 there was no effect of SQ-LNS on linear infant growth⁹⁴. Furthermore, SQ-LNS was provided to both 474 475 mothers during pregnancy and infants starting at 6mo postpartum, active control interventions (ironfolate or multiple micronutrient supplements) were provided to mothers^{48,94}, and 16S rRNA gene 476 477 amplification and sequencing were used to characterize the microbiota which can affect both taxon detection (including Bifidobacterium) and study results⁹⁵. A second RCT reported evidence for effect 478 479 modification of iron supplementation on growth by maternal FUT2 status, where infants of FUT2mothers randomized to iron supplementation showed greater declines in LAZ than infants of FUT2+ 480 mothers⁹⁶. In addition, a third, recent RCT found that suppression of *B. longum* by amoxicillin allowed 481 482 the gut microbiota of children with SAM to better adapt to a solid-food diet by reducing the abundance 483 of taxa specialized for breast milk utilization, resulting in improved anthropometric indicators of infant nutritional status⁹⁷. However, it is essential to note that *B. longum* subspecies *infantis* is a critical early 484 485 infant gut bacteria with important benefits for infant health, including protection from enteric 486 pathogens⁹⁸, immune system development⁹⁹, and reducing asthma risk¹⁰⁰. *B. longum* subspecies *infantis* also improved ponderal growth when administered to infants ~4mo of age with SAM in two RCTs^{101,102}. 487 488 However, the effects on LAZ were not statistically significant. Our work complements this literature. Our 489 findings suggest that a shift away from a "less mature" microbiome, characterized by a high abundance

of *B. longum* and carriage of strains that are better suited to HMO metabolism, may be critical to
support efficacy of nutrient supplements that start with the introduction of complementary feeding; and
we identify maternal drivers of early infant *B. longum* abundance and strain carriage which, if further
elucidated, may be employed to shape the infant microbiome into a more favorable composition at this
critical time in infancy.

495 There are some limitations of this work. First, from our cohort of 1169 HIV-unexposed infants, we 496 had microbiome data on 172 infants. However, infants included in our analyses were comparable to 497 infants who excluded (Table S6). Also, mother-infant FUT2+/FUT3- phenotype, which was an important 498 determinant of B. longum abundance and strain cluster detection, modified the impact of IYCF on 499 stunting in the larger sample of 792 infants without measured microbiome data in a way that was 500 consistent with our microbiome results. That said, our small sample size may have limited power to 501 detect effect modification by other taxa that are indicative of a "more mature" post-weaning 502 microbiome. Our analyses were not able to investigate effect modification by actual microbial metabolic 503 activity, maternal HMO composition or infant gut glycobiome, which would require multi-omics 504 approaches such as metatranscriptomics and metabolomics. Finally, it is possible that the delay in 505 microbiome maturation we characterized may reflect some reverse causality, where sick or non-thriving 506 children are put to the breast more with higher relative breastmilk intake. However, this behavior would 507 need to systematically occur less often in the subset of mothers and their infants who were discordant 508 for FUT2+/FUT3- that we describe to fully explain our results, thus we think this explanation is unlikely. 509 In conclusion, we present analyses of moderators of IYCF impact on infant stunting at 18mo in an 510 RCT of IYCF using SQ-LNS in rural Zimbabwe. We report that (i) infant microbiome species maturation, 511 characterized by a shift from B. longum dominance, particularly B. longum strains that are most similar 512 to the proficient HMO utilizer subspecies infantis, was associated with increased IYCF reduction of 513 stunting risk at age 18mo; (ii) discordance in mother-infant FUT2+/FUT3- phenotype, where the mother

514	had the phenotype but the infant did not, was associated with increased IYCF reduction of stunting risk;
515	and (iii) reduction in <i>B. longum</i> relative abundance was also determined by mother-infant FUT2+/FUT3-
516	phenotype. Future work should investigate how differences between maternal HMOs and infant gut
517	glycans determine gut Bifidobacterium species and strain composition, and investigate how to tailor
518	interventions at the introduction of complementary feeding to balance infant nutritional needs with
519	age-related microbiome composition and function to prevent stunting.
520	
521	Figure legends
522	Figure 1. Infant growth trajectories and growth velocities vary by IYCF arm and mother-infant
523	FUT2+/FUT3- phenotype.
524	(A) LAZ by infant age from 1-18mo (n=792), stratified by IYCF arm (light grey, no IYCF; dark grey, IYCF)
525	and mother-infant FUT2+/FUT3- phenotype (<i>both, none, infant only</i> or <i>mother only</i>). Lines illustrate
526	average trajectories. Shaded areas are 95% confidence bands. Infants randomized to IYCF in the mother
527	only group had a less steep decline in LAZ trajectories on average compared to infants randomized to no
528	IYCF.
529	(B) Violin plots of LAZ velocity from 6-18mo of age, stratified by IYCF arm (light grey, no IYCF; dark grey,
530	IYCF) and mother-infant FUT2+/FUT3- phenotype (both, none, infant only or mother only). Open circles
531	with error bars in the center of each panel indicate mean LAZ velocity and 95%Cls. All groups of infants
532	had negative LAZ velocities on average, but infants in the mother only group who were randomized to
533	IYCF had higher LAZ velocity on average, contributing to a less steep decline in LAZ over time and a
534	smaller proportion of infants stunted at 18mo.
535	
536	Figure 2. Infant growth trajectories and growth velocities vary by IYCF arm and infant gut

Bifidobacterium longum relative abundance.

(A) LAZ by infant age from 1-18mo (n=53), stratified by IYCF arm and *Bifidobacterium longum* relative
abundance (light grey, ≤median relative abundance; dark grey, >median relative abundance). Thin lines
illustrate individual trajectories. Thick lines show average trajectories. Infants randomized to IYCF who
were above the median relative abundance had a declining growth trajectory on average, while infants
below the median did not.

(B) Violin plots of LAZ velocity from 6-18mo of age, stratified by IYCF arm (light grey, no IYCF; dark grey,
IYCF) and mother-infant FUT2+/FUT3- phenotype (*both, none, infant only* or *mother only*). Open circles
with error bars indicate mean LAZ velocity and 95%CIs. All groups of infants had negative LAZ velocities
on average. However, LAZ velocity trended toward being higher in the group with relative abundance
below the median. The 95% confidence intervals overlap, but the higher LAZ velocity contributed to a
less steep decline in LAZ over time and a smaller proportion of stunted infants at 18mo.

549

550 Figure 3. Bifidobacterium longum strains most similar to subspecies infantis dominate the early infant 551 gut microbiome. Ordination plots of PCoA with Jaccard dissimilarities calculated using the pangenome 552 profiles of dominant Bifidobacterium longum strains in fecal specimens (N=284) generated using 553 PanPhlan3.0. Three clusters of *B. longum* strains were identifiable. Individual strains and indicated by 554 small circles. Those in the same cluster are enclosed by a large ellipse and are differentiated by both the 555 color of the ellipse and the border color of the small circle (blue, *infantis*; dark green, *longum*; red, *suis*). 556 Filled small circles indicate reference strains (light blue, *infantis*; pink, *suis*, light green, *longum*; grey, 557 unclassified). Open small circles indicate SHINE strains. Subspecies infantis reference strains 558 predominantly grouped with the largest cluster (blue ellipse, infantis cluster). Subspecies longum 559 reference strains predominantly grouped with the second largest cluster (dark green ellipse, longum 560 cluster). The remaining cluster (red ellipse, suis cluster) grouped with subspecies suis and longum.

562 Figure 4. SHINE infant Bifidobacterium longum infantis cluster strains are better adapted for human 563 milk oligosaccharide utilization and protection against pathogens than suis and longum cluster strains. 564 (A) Heatmap of UniProt gene family presence in SHINE infant *Bifidobacterium longum* strains (N=284). 565 UniProt gene family presence is indicated in grey. The horizontal bar at the top indicates strain cluster 566 (blue, infantis; dark green, longum; red, suis). Vertical bars from left to right indicate: UniProt gene 567 families that differed in prevalence between the *infantis* and *longum* cluster by two-sided Fisher's Exact 568 test after FDR correction (red); UniProt gene families that differed in prevalence between the *infantis* 569 and suis cluster by two-sided Fisher's Exact test after FDR correction (red); Biological Process GO groups; 570 CAZymes; and Transporter class. Only gene families with evidence of overrepresentation in a Biological 571 Process, CAZyme or Transporter class by one-sided Fisher's Exact Test are presented. 572 (B) Heatmap of MetaCyc pathway presence in SHINE infant *Bifidobacterium longum* strains (N=284). 573 MetaCyc pathway presence is indicated in grey. The horizontal bar at the top indicates strain cluster 574 (blue, infantis; dark green, longum; red, suis). Vertical bars from left to right indicate: MetaCyc pathways 575 that differed in prevalence between the infantis and longum cluster by two-sided Fisher's Exact test 576 after FDR correction (red); MetaCyc pathways that differed in prevalence between the infantis and suis 577 cluster by two-sided Fisher's Exact test after FDR correction (red); MetaCyc pathway type. Only 578 pathways with evidence of overrepresentation in a pathway type by one-sided Fisher's Exact Test are 579 presented.

580

581 Methods

582 Study design and participants

The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial was a 2x2 factorial cluster-randomized trial that enrolled 5280 pregnant women at a median age of 12.5 weeks gestation between November 2012 and March 2015 to test the impact of improved household water quality, sanitation, and hygiene (WASH) and improved infant and young child feeding (IYCF) via provision of SQ-LNS to the infant from
age 6mo-18mo, on linear growth and anemia at age 18mo. A detailed description of the SHINE trial
design and methods has been published^{51,103}.

589 Briefly, research nurses made home visits twice during pregnancy and at infant ages 1, 3, 6, 12, and 18 months. At baseline, maternal education and age, household wealth¹⁰⁴, existing water and sanitation 590 services, and household food security¹⁰⁵ were assessed, and mothers were tested for HIV via a rapid 591 592 testing algorithm. Infant birth date, weight, and delivery details were transcribed from health facility 593 records. Gestational age at delivery was calculated from the date of the mother's last menstrual period 594 ascertained at baseline. Infant weight, length, and mid-upper arm circumference were measured at 595 every postnatal visit. Nurses were standardized against a gold-standard anthropometrist every 6 596 months, with retraining provided to those who failed to meet predefined criteria.

597 Part-way through the trial (from mid-2014 onwards) mother-infant pairs were invited to join a
598 substudy to collect additional biological specimens. Women were informed about the substudy at their
599 32-week gestation visit and those with live births were enrolled at the 1-month postnatal visit, or as
600 soon as possible thereafter^{106,107}.

601

602 Specimen collection and processing

Mothers collected fecal specimens prior to the research nurse visit. Fecal specimens were placed in a cold box and transported to the field laboratory, where they were stored at -80°C until transfer to the central laboratory in Harare for long-term archiving at -80°C, with generator back-up. Fecal specimens were transferred via private courier on dry ice from Harare, Zimbabwe to Vancouver, British Columbia for metagenomic analyses.

608 The Qiagen DNeasy PowerSoil Kit was used to extract total DNA from 200mg of feces, according to 609 manufacturer's instructions. Paired-end libraries were constructed using the Illumina TruSeq kit and using New England Biosystem TruSeq compatible library preparation reagents. Libraries were sequenced
at the British Columbia Genome Sciences Centre using the Illumina HiSeq 2500 platform. Forty-eight
libraries were pooled and included per sequencing lane. Negative controls were included to capture
microbial contamination in the DNA extraction and library preparation steps.

- The analyses presented here utilize data and specimens from HIV-uninfected mothers and their
- infants enrolled in the specimen collection substudy. The fecal microbiome was characterized in 354
- 616 specimens collected from 172 HIV-unexposed infants from 1 to 18mo of age. A mean(sd) of 2.0(1.0)
- samples were analyzed per child. Infants included in these analyses largely resembled the population of
- 618 live-born infants from the wider SHINE trial who were not included in these analyses (Table S6).
- However, infants in the current analyses had slightly older mothers and longer gestational ages, and

620 fewer were born during the hungry season, but more were in a household that met the minimum

- 621 dietary diversity score (Table S6). Overall, the majority were born by vaginal delivery (91.6%) in an
- 622 institution (91.5%) and were exclusively breastfed (83.2% at 3 months). The prevalence of stunting was
- 623 26.9% at 18mo in this sub-study (Table S6).
- 624

625 Bioinformatics

626 Sequenced reads were trimmed of adapters and filtered to remove low-guality, short (<60 base-627 pairs), and duplicate reads, as well as those of human, other animal or plant origin using KneadData with 628 default settings. Overall, 354 unique whole metagenome sequencing datasets were used from fecal 629 specimens collected from 1mo to 18mo from 172 infants with available mother and infant FUT2 and 630 FUT3 phenotypes (Figure S2). On average, 10.8±3.7 million paired end quality-filtered reads were 631 generated per sample. Assessment of negative controls and technical variation have been previously reported⁶⁴. Species composition was determined by mapping reads to clade-specific markers using 632 633 MetaPhIAn3, while functional gene and metabolic pathway composition was determined using

HUMAnN3 against the UniRef90 database, both with default settings⁵². Bacterial species and pathway
abundance estimates were normalized to relative abundances. UniProt gene family profiles were
generated for dominant *B. longum* strains in fecal metagenomes with sufficient coverage for
pangenome analysis using PanPhlan3⁵². To facilitate interpretation of UniProt gene family profiles, the
minimum set of biological pathways sufficient to explain the gene families identified in each strain was
determined using MinPath with default settings⁵⁸ and the MetaCyc database⁵⁷.

640

641 Assessment of FUT2 and FUT3 status

642 Saliva samples were collected by oral swab from mothers and infants. Available saliva from any 643 follow-up visit was selected to assess FUT2 and FUT3 status. Secretor versus non-secretor (FUT2) and 644 Lewis-positive versus Lewis-null (FUT3) status were ascertained for infants and their mothers using a previously reported phenotyping assay¹⁰⁸. We defined FUT2 and FUT3 phenotype combinations as 645 646 Lewis-positive non-secretors (FUT2-/FUT3+), Lewis-positive secretors (FUT+/FUT3+), or Lewis-null 647 secretors (FUT2+/FUT3-) (Table S11) according to the histo-blood group antigen synthesis pathways 648 defined in Figure S1. Paired mother-infant phenotype concordance or discordance was defined as 649 presented in Table S1.

Of 1,169 mother-infant pairs, 999 (85.4%) mothers and 1104 (94.4%) infants were tested. Of these,

FUT2 or FUT3 status could be determined in 889 (76.0%) and 999 (85.4%) mothers and infants,

652 respectively (Table S11). Of those whose FUT2 or FUT3 status could be ascertained, secretors were the

most frequent FUT2 phenotype (88.1% and 85.6% in mothers and infants respectively), while Lewis-

positive was the most frequent FUT3 phenotype (76.8% and 74.9% in mothers and infants, respectively)

(Table S11). Most mothers and infants were Lewis-positive secretors (60.5% and 64.9%, respectively),

656 followed by FUT2+/FUT3- (25.1% and 23.2%, respectively), and Lewis-positive non-secretors (14.4% and

657 11.9%, respectively) (Table S1).

658

659 Statistical analyses

660 Infant characteristics that explain species β -diversity were evaluated using constrained principal coordinates analysis (PCoA) of Bray-Curtis dissimilarities (*capscale*)¹⁰⁹. Characteristics of interest 661 662 included factors that are known to be correlated with microbiome composition (infant age, sex, EBF at 663 3mo, dietary diversity, maternal and infant FUT2 and FUT3 phenotype). Statistical significance was 664 tested by permutational analysis of variance using distance matrices with 1000 permutations (adonis2)¹¹⁰. We then developed a final multivariable constrained PCoA model that included covariates 665 666 which explained a significant fraction (p<0.05) of the variance in microbiome composition (infant age at 667 specimen collection), as well as mother-infant FUT2+/FUT3- discordance given our a prior hypothesis 668 that FUT2 and FUT3 phenotypes are important determinants of infant microbiome composition and our 669 finding that mother-infant FUT2+/FUT3- discordance was an important modifier of IYCF efficacy to 670 reduce stunting at 18mo. Constrained PCoA axis scores in the final multivariable model represented 671 changes in microbiome composition (species turnover) along gradients defined by each infant 672 characteristic included in the full model. 673 Since the IYCF intervention was started at the 6mo follow-up visit, we assessed interaction between 674 randomization to IYCF and mother-infant FUT2+/FUT3- discordance or microbiome composition using 675 data from the 6mo visit as covariates. The primary outcome was stunting at 18mo and LAZ at 18mo was 676 a secondary outcome. We fitted separate models for stunting and LAZ at 18mo. Interaction was assessed on the additive risk difference scale, which is most appropriate for statistical estimation of 677 synergistic biological effects¹¹¹. We used generalized linear models (glm) with a Gaussian distribution, an 678 identity link, sandwich standard errors (sandwich)¹¹² and an IYCF-by-mother-infant FUT2+/FUT3-679 680 phenotype interaction term. We repeated these analyses using IYCF-by-PCoA axis score interaction 681 terms, where PCoA axis scores were derived from the final multivariable constrained PCoA model. One

682 model was fitted per constrained PCoA axis. For species that were strongly associated with PCoA axis 683 scores (loadings > 0.5 or < -0.5), analyses were repeated to assess IYCF-by-species interactions. We fitted 684 a separate model for each species of interest. Models also included IYCF, infant sex, mother-infant FUT2+/FUT3- discordance, infant age at specimen collection, an indicator of whether infants met the 685 686 minimum dietary diversity score at specimen collection, and LAZ at specimen collection. We did not 687 include WASH arm because, in prior analyses, the SHINE WASH intervention did not affect stunting or LAZ at 18mo⁵¹ nor infant gut microbiome composition⁶⁴. P-values were adjusted for multiple hypothesis 688 testing to preserve the false discovery rate¹¹³. 689

690

691 Identification and analysis of Bifidobacterium longum strain clusters

B. longum strain profiles produced with PanPhlan3.0, which indicate whether UniProt gene families are present in a strain¹¹⁴, were converted to Jaccard dissimilarity matrices and visualized by PCoA to ascertain the existence of strain clusters (*capscale*). Three clusters were identified, and strain cluster membership was determined by hierarchical clustering of Jaccard dissimilarities and Ward's error sum of squares algorithm (*hclust*)¹¹⁵. Hierarchical clustering dendrograms were cut at a height to obtain three clusters.

698 Differences in UniProt gene family profiles between *B. longum* strain clusters were determined by 699 two-sided Fisher's Exact test (*fisher.test*), with adjustment for multiple hypothesis testing to preserve the false discovery rate¹¹³, and were visualized using heatmaps (*heatmap3*). 3260 UniProt gene families 700 701 were differentially present between strain clusters after FDR-adjustment. We performed 702 overrepresentation analyses⁵³ using one-sided Fisher's Exact tests (*fisher.test*) to determine whether the differentially present gene families were more likely to function as particular CAZymes⁵⁵ or 703 transporters⁵⁶, or in specific GO biological processes⁵⁴. These analyses were repeated using the 704 biological pathways determined with MinPath⁵⁸. 115 pathways were differentially present between 705

strain clusters after FDR-adjustment. We performed overrepresentation analyses of these pathways to
 determine whether they were more likely to have particular biological functions defined by MetaCyc
 pathway types.

709

710 Predictors of Bifidobacterium relative abundance and strain detection

Predictors of *B. longum* relative abundance over time were assessed using mixed-effects zeroinflated beta regression estimated by restricted maximum likelihood (*gamlss*)¹¹⁶. The model included
infant age at specimen collection, sex, EBF at 3mo, minimum infant dietary diversity at specimen
collection, and mother-infant FUT2+/FUT3- discordance, with random intercepts (*re*) and a first order
autocorrelation structure (*corCAR1*).
Predictors of *B. longum* strain cluster were assessed by logistic regression (*glm*) using an indicator of
strain cluster presence as the dependent variable, with the same covariates, and sandwich standard

errors. An individual model was fitted separately for each cluster. Bias corrected¹¹⁷ logistic regression
was used to facilitate stable parameter estimation due to separation resulting from the small sample
size¹¹⁸.

All statistical analyses were conducted in R version 4.2.0. PCoA and adonis2 were performed using the *vegan* package¹¹⁹. Heatmaps were generated with *heatmap3*. Mixed-effects zero-inflated beta regression was performed using the *gamlss* package¹²⁰. Bias corrected logistic regression models were fitted using the *brgIm2* package. Sandwich standard errors were generated with the *sandwich* package.

725

726 *Resource availability*

727 Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled
by the lead contact, Ethan Gough (<u>egough1@jh.edu</u>).

730	Materials availability
731	This study did not generate new unique reagents.
732	Data and code availability
733	The raw metagenome sequencing data generated in this study have been deposited in the European
734	Bioinformatics Database under accession code PRJEB51728. Final processed and annotated
735	metagenome sequencing data files (taxa and pathways) are available at
736	https://doi.org/10.5281/zenodo.7471082. Epidemiologic data files are available at Code for statistical
737	analyses are available from the corresponding author upon request.
738	
739	Supplemental Tables
740	Table S8. Overrepresentation of UniProt gene families and Metacyc pathways, which differ between
741	strain clusters, by GO biological process, CAZyme or Transporter class or Metacyc pathway type.
742	
743	Ethics approvals
744	All SHINE mothers provided written informed consent. The Medical Research Council of Zimbabwe
745	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University
745 746	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome
745 746 747	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940).
745 746 747 748	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940).
745 746 747 748 749	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940). Acknowledgments
745 746 747 748 749 750	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940). Acknowledgments We thank all the mothers, babies, and their families who participated in the SHINE trial and all members
745 746 747 748 749 750 751	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940). Acknowledgments We thank all the mothers, babies, and their families who participated in the SHINE trial and all members of the SHINE trial team (all members listed here: https://doi.org/10.1093/cid/civ844). We particularly
745 746 747 748 749 750 751 752	(MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia Ethics Board (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940). Acknowledgments We thank all the mothers, babies, and their families who participated in the SHINE trial and all members of the SHINE trial team (all members listed here: https://doi.org/10.1093/cid/civ844). We particularly thank the leadership and staff of the Ministry of Health and Child Care in Chirumanzu and Shurugwi

754 in operationalization of the study procedures, the Ministry of Local Government officials in each district 755 who supported and facilitated field operations, Phillipa Rambanepasi and her team for proficient 756 management of all the finances, Virginia Sauramba for management of compliance issues, and the 757 programme officers at the Bill & Melinda Gates Foundation and the Department for International 758 Development (UK Aid), who enthusiastically worked with us over a long period to make SHINE happen. 759 Funding was from the Bill & Melinda Gates Foundation (OPP1021542 and OPP1143707; J.H.H. and 760 A.J.P.), with a subcontract to the University of British Columbia (20R25498; A.R.M.). United Kingdom 761 Department for International Development (DFID/UKAID; J.H.H. and A.J.P.). Wellcome Trust 762 (093768/Z/10/Z, 108065/Z/15/Z, 206455/Z/17/Z, 203905/Z/16/Z and 210807/Z/18/Z; A.J.P., R.C.R. and 763 C.E.). Swiss Agency for Development and Cooperation (J.H.H. and A.J.P.). US National Institutes of Health 764 (2R01HD060338-06; J.H.H.). UNICEF (PCA-2017-0002; J.H.H. and A.J.P.). The Nutricia Research 765 Foundation (2021-52; E.K.G.) The funders had no role in the design of the study and collection, analysis, 766 and interpretation of data and in writing the manuscript.

767

Author contributions: A.R.M., L.E.S., R.J.S., M.N.N.M., J.H.H. and A.J.P. conceptualized and designed the
study. K.M., R.N., B.C., F.D.M., N.V.T., J.T., and B.M. collected data and biospecimens. H.M.G., I.B.,
S.K.G., R.C.R., F.F. and L.C. processed fecal specimens. M.K. conducted laboratory analyses to ascertain
FUT2 and FUT3 status. C.E., J.C. and E.K.G. developed the FUT2 and FUT3 analysis plan. E.K.G. developed
and conducted the microbiome statistical analysis plan. T.J.E. and E.K.G. conducted bioinformatics.
A.R.M. and E.K.G. analyzed and interpreted the data. E.K.G. wrote the original manuscript draft. All
authors reviewed the manuscript. A.R.M., A.J.P. and J.H.H. supervised and verified the data.

776	Declaration of interests: T.J.E. was paid a scientific consulting fee in relation to the analysis of the data
777	presented here by the Zvitambo Institute for Maternal and Child Health Research. All other authors
778	declare no competing interests.
779	
780	
781	
782	
783	
784	
785	
786	
787	
788	
789	
790	
791	
792	
793	
794	

Table 1. Multivariable regression model¹ to estimate modification of IYCF on stunting at 18mo by motherinfant Lewis-null secretor phenotype discordance among 792 infants in whom mother and infant FUT2 and FUT3 status was ascertained

	<u>Main Effect</u>		Difference-in-Differences for IYCF by FUT2 and FUT3 phenotype combination			
	PD (95%Cl)	p- value	Adjusted p- value ²	PD (95%Cl)	p- value	Adjusted p- value ²
Both FUT2+/FUT3-	ref	ref	ref	ref	ref	
None FUT2+/FUT3-	0.13(0.01,0.25)	0.041	0.330	-0.21(-0.42,-0.01)	0.039	0.118
Infant only FUT2+/FUT3-	0.15(-0.03,0.33)	0.094	0.277	-0.21(-0.48,0.06)	0.127	0.191
Mom only FUT2+/FUT3-	0.29(0.14,0.44)	0.000	0.007	-0.33(-0.55,-0.10)	0.005	0.015
non-IYCF	ref	ref	ref			
IYCF	0.16(-0.02,0.35)	0.138	0.177			

¹Covariates include season of birth, birthweight, infant sex, ever exclusive breastfeeding at 3mo, age at the 6mo visit, infant WHZ at the 6mo visit, and infant LAZ at the 6mo visit

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method

PD, prevalence difference; 95%Cl, 95% confidence interval; ref, referent

Table 2. Multivariable regression models ¹ to estimate modification of IYCF on stunting at 18mo b	y
infant gut microbiome species turnover in 53 infants	

	PD(95%CI)	p-value	Adjusted p-value ²
PCoA Axis 1		<u>n/N=17/53</u>	
IYCF	-0.51(-0.99,-0.12)	0.009	0.045
PC1	0.21(-0.99,0.45)	0.085	0.204
PC1-by-IYCF ³	-0.76(-0.99,-0.32)	0.001	0.003
PCoA Axis 2		<u>n/N=17/53</u>	
IYCF	-0.14(-0.99,0.12)	0.293	0.469
PC2	-0.06(-0.99,-0.01)	0.020	0.068
PC2-by-IYCF ³	0.14(0.07,0.21)	<0.001	0.001
PCoA Axis 3		<u>n/N=17/53</u>	
IYCF	0.09(-0.99,0.39)	0.543	0.686
PC3	0.04(-0.99,0.09)	0.156	0.340
PC3-by-IYCF ³	-0.08(-0.99,-0.02)	0.016	0.032
PCoA Axis 4		<u>n/N=17/53</u>	
IYCF	0.03(-0.99,0.31)	0.847	0.924
PC4	0.00(-0.99,0.06)	0.994	0.994
PC4-by-IYCF ³	0.03(-0.99,0.12)	0.438	0.501

¹Covariates include birthweight, infant sex, age at the 6mo visit, infant LAZ at the 6mo visit, infant diet diveristy score at the 6mo visit, and mother-infant Lewis-null secretor phenotype discordance coded as both, none, infant only or mother only

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method

³Differences-in-differences

PD, prevalence difference; 95%Cl, 95% confidence interval

Table 3. Multivariable regression models ¹	to estimate modification of IYCF on stunting at 18mo by
infant gut microbiome species in 53 infan	ts

	PD(95%CI)	p-value	Adjusted p-value ²
Bifidobacterium longum		<u>n/N=17/53</u>	
IYCF	-0.16(-0.43,0.10)	0.232	0.976
B.longum	-0.24(-0.43,-0.05)	0.014	0.068
B.longum-by-IYCF ³	0.50(0.26,0.74)	<0.001	<0.001
Bifidobacterium pseudocatenulatum		<u>n/N=17/53</u>	
IYCF	-0.54(-1.02,-0.06)	0.029	0.304
B.pseudocatenulatum	1.82(0.48,3.15)	0.008	0.051
B.pseudocatenulatum-by-IYCF ³	-2.00(-3.33,-0.68)	0.003	0.014
Escherichia coli		<u>n/N=17/53</u>	
IYCF	0.04(-0.25,0.33)	0.774	1.000
E.coli	0.01(-0.10,0.13)	0.823	0.859
E.coli-by-IYCF ³	-0.07(-0.21,0.08)	0.362	0.592
Dorea longicatena		<u>n/N=17/53</u>	
IYCF	0.02(-0.27,0.31)	0.896	1.000
D.longicatena	-0.02(-0.13,0.09)	0.725	0.859
D.longicatena-by-IYCF ³	0.03(-0.39,0.44)	0.898	0.898
Dorea formicigenerans		<u>n/N=17/53</u>	
IYCF	-0.18(-0.37,0.01)	0.062	0.324
D.formicigenerans	-0.18(-0.33,-0.03)	0.018	0.073
D.formicigenerans-by-IYCF ³	-0.50(-1.00,-0.00)	0.048	0.145

¹Covariates include birthweight, infant sex, age at the 6mo visit, infant LAZ at the 6mo visit, infant diet diversity score at the 6mo visit, and mother-infant Lewis-null secretor phenotype discordance coded as both, none, infant only or mother only

²Adjusted for multiple hypothesis testing by the Benjamini-Hochberg method

³Differences-in-differences

PD, prevalence difference; 95%Cl, 95% confidence interval

822

823

824

825

020		
827		
828	Refe	rences
829 830 831 832	1.	United Nations Children's Fund, World Health Organization, and The World Bank (2019). Levels and trends in child malnutrition: key findings of the 2019 Edition of the Joint Child Malnutrition Estimates – UNICEF Regions. (United Nations Children's Fund (UNICEF), World Health Organization, International Bank for Reconstruction and Development/The World Bank).
833 834	2.	Onis, M.D., Garza, C., Onyango, A.W., and Martorell, R. (2006). WHO child growth standards. Acta Paediatrica 95, 1–104.
835 836 837	3.	Benjamin-Chung, J., Mertens, A., Colford, J.M., Hubbard, A.E., van der Laan, M.J., Coyle, J., Sofrygin, O., Cai, W., Nguyen, A., Pokpongkiat, N.N., et al. (2023). Early-childhood linear growth faltering in low- and middle-income countries. Nature <i>621</i> , 550–557.
838 839 840	4.	Gough, E.K., Moodie, E.E.M., Prendergast, A.J., Ntozini, R., Moulton, L.H., Humphrey, J.H., Manges, A.R., Stephens, D.A., Moodie, E.E.M., Prendergast, A.J., et al. (2016). Linear growth trajectories in Zimbabwean infants. American Journal of Clinical Nutrition <i>104</i> , 1616–1627.
841 842 843 844	5.	Adair, L.S.L.L.S., Fall, C.H.D.D., Osmond, C., Stein, A.D.A.A.D., Martorell, R., Ramirez-Zea, M., Sachdev, H.S., Dahly, D.L., Bas, I., Norris, S.A., et al. (2013). Associations of linear growth and relative weight gain during early life with adult health and human capital in countries of low and middle income: Findings from five birth cohort studies. The Lancet <i>382</i> , 525–534.
845 846 847	6.	Victora, C.G., Adair, L., Fall, C., Hallal, P.C., Martorell, R., Richter, L., and Sachdev, H.S. (2008). Maternal and child undernutrition: consequences for adult health and human capital. Lancet <i>371</i> , 340–357.
848 849 850 851	7.	Vollmer, S., Harttgen, K., Subramanyam, M.A., Finlay, J., Klasen, S., and Subramanian, S.V. (2014). Association between economic growth and early childhood undernutrition: evidence from 121 Demographic and Health Surveys from 36 low-income and middle-income countries. The Lancet Global Health <i>2</i> , e225-234.
852 853 854 855	8.	Dewey, K.G., Wessells, K.R., Arnold, C.D., Prado, E.L., Abbeddou, S., Adu-Afarwuah, S., Ali, H., Arnold, B.F., Ashorn, P., Ashorn, U., et al. (2021). Characteristics that modify the effect of small- quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr <i>114</i> , 15S-42S.
856 857	9.	Dewey, K.G., Arnold, C.D., Wessells, K.R., Prado, E.L., Abbeddou, S., Adu-Afarwuah, S., Ali, H., Arnold, B.F., Ashorn, P., Ashorn, U., et al. (2022). Preventive small-quantity lipid-based nutrient

858supplements reduce severe wasting and severe stunting among young children: an individual859participant data meta-analysis of randomized controlled trials. Am J Clin Nutr 116, 1314–1333.

- Ruel, M.T., Alderman, H., and Maternal Child Nutrition Study Group (2013). Nutrition-sensitive
 interventions and programmes: how can they help to accelerate progress in improving maternal
 and child nutrition? Lancet *382*, 536–551.
- 11. Arrieta, M.-C., Stiemsma, L.T., Amenyogbe, N., Brown, E.M., and Finlay, B. (2014). The intestinal microbiome in early life: health and disease. Frontiers in Immunology *5*, 427.
- Jones, H.J., Bourke, C.D., Swann, J.R., and Robertson, R.C. (2023). Malnourished Microbes: Host–
 Microbiome Interactions in Child Undernutrition. Annual Review of Nutrition *43*, 327–353.
- 86713.Robertson, R.C., Manges, A.R., Finlay, B.B., and Prendergast, A.J. (2019). The Human Microbiome868and Child Growth First 1000 Days and Beyond. Trends Microbiol 27, 131–147.
- Subramanian, S., Huq, S., Yatsunenko, T., Haque, R., Mahfuz, M., Alam, M.A., Benezra, A.,
 DeStefano, J., Meier, M.F., Muegge, B.D., et al. (2014). Persistent gut microbiota immaturity in
 malnourished Bangladeshi children. Nature *510*, 417–421.
- 15. Zhao, G., Vatanen, T., Droit, L., Park, A., Kostic, A.D., Poon, T.W., Vlamakis, H., Siljander, H.,
 Härkönen, T., Hämäläinen, A.M., et al. (2017). Intestinal virome changes precede autoimmunity in
 type I diabetes-susceptible children. Proceedings of the National Academy of Sciences of the
 United States of America *114*, E6166–E6175. 10.1073/pnas.1706359114.
- Ho, N.T., Li, F., Lee-Sarwar, K.A., Tun, H.M., Brown, B.P., Pannaraj, P.S., Bender, J.M., Azad, M.B.,
 Thompson, A.L., Weiss, S.T., et al. (2018). Meta-analysis of effects of exclusive breastfeeding on
 infant gut microbiota across populations. Nature Communications *9*, 4169. 10.1038/s41467-01806473-x.

17. Reyes, A., Blanton, L.V., Cao, S., Zhao, G., Manary, M., Trehan, I., Smith, M.I., Wang, D., Virgin,
H.W., Rohwer, F., et al. (2015). Gut DNA viromes of Malawian twins discordant for severe acute
malnutrition. Proceedings of the National Academy of Sciences of the United States of America
112, 11941–11946. 10.1073/pnas.1514285112.

- 18. Gough, E.K., Stephens, D.A., Moodie, E.M., Prendergast, A.J., Stoltzfus, R.J., Humphrey, J.H., and
 Manges, A.R. (2016). Linear growth faltering in infants is associated with Acidaminococcus sp. and
 community-level changes in the gut microbiota. Microbiome *3*, 24.
- Ghosh, T.S., Gupta, S.S., Bhattacharya, T., Yadav, D., Barik, A., Chowdhury, A., Das, B., Mande, S.S.,
 and Nair, G.B. (2014). Gut Microbiomes of Indian Children of Varying Nutritional Status. PLoS ONE
 9, e95547.
- 890 20. Gupta, S.S., Mohammed, M.H., Ghosh, T.S., Kanungo, S., Nair, G.B., and Mande, S.S. (2011).
 891 Metagenome of the gut of a malnourished child. Gut Pathog *3*, 7.
- Huey, S.L., Jiang, L., Fedarko, M.W., McDonald, D., Martino, C., Ali, F., Russell, D.G., Udipi, S.A.,
 Thorat, A., Thakker, V., et al. (2020). Nutrition and the Gut Microbiota in 10- to 18-Month-Old
 Children Living in Urban Slums of Mumbai, India. mSphere 5, e00731-20.

- 22. Digitale, J., Sié, A., Coulibaly, B., Ouermi, L., Dah, C., Tapsoba, C., Bärnighausen, T., Lebas, E., Arzika,
 A.M., Glymour, M.M., et al. (2020). Gut Bacterial Diversity and Growth among Preschool Children
 in Burkina Faso. Am J Trop Med Hyg *103*, 2568–2573.
- 23. Collard, J.-M., Andrianonimiadana, L., Habib, A., Rakotondrainipiana, M., Andriantsalama, P.,
 Randriamparany, R., Rabenandrasana, M. a. N., Weill, F.-X., Sauvonnet, N., Randremanana, R.V., et
 al. (2022). High prevalence of small intestine bacteria overgrowth and asymptomatic carriage of
 enteric pathogens in stunted children in Antananarivo, Madagascar. PLoS Negl Trop Dis *16*,
 e0009849.
- 24. Kamng'ona, A.W., Young, R., Arnold, C.D., Kortekangas, E., Patson, N., Jorgensen, J.M., Prado, E.L.,
 24. Chaima, D., Malamba, C., Ashorn, U., et al. (2019). The association of gut microbiota characteristics
 25. in Malawian infants with growth and inflammation. Scientific Reports *9*.
- 906 25. Perin, J., Burrowes, V., Almeida, M., Ahmed, S., Haque, R., Parvin, T., Biswas, S., Azmi, I.J., Bhuyian,
 907 S.I., Talukder, K.A., et al. (2020). A Retrospective Case-Control Study of the Relationship between
 908 the Gut Microbiota, Enteropathy, and Child Growth. The American journal of tropical medicine and
 909 hygiene.
- Brown, E.M., Wlodarska, M., Willing, B. p, Vonaesch, P., Han, J., Reynolds, L.A., Arriet, M.-C., Uhrig,
 M., Scholz, R., Partida, O., et al. (2015). Diet and specific microbial exposure trigger features of
 environmental enteropathy in a novel murine model. Nature Communications *6*, 7806.
- 27. Kau, A.L., Planer, J.D., Liu, J., Rao, S., Yatsunenko, T., Trehan, I., Manary, M.J., Liu, T.-C.,
 Stappenbeck, T.S., Maleta, K.M., et al. (2015). Functional characterization of IgA-targeted bacterial
 taxa from undernourished Malawian children that produce diet-dependent enteropathy. Science
 Translational Medicine 7, 276ra24-276ra24.
- Salli, K., Hirvonen, J., Siitonen, J., Ahonen, I., Anglenius, H., and Maukonen, J. (2021). Selective
 Utilization of the Human Milk Oligosaccharides 2^I/₂-Fucosyllactose, 3-Fucosyllactose, and
 Difucosyllactose by Various Probiotic and Pathogenic Bacteria. Journal of Agricultural and Food
 Chemistry 69.
- 29. Davis, J.C.C., Totten, S.M., Huang, J.O., Nagshbandi, S., Kirmiz, N., Garrido, D.A., Lewis, Z.T., Wu,
 22. L.D., Smilowitz, J.T., German, J.B., et al. (2016). Identification of Oligosaccharides in Feces of
 23. Breast-fed Infants and Their Correlation with the Gut Microbial Community*. Molecular & Cellular
 24. Proteomics *15*, 2987–3002.
- 30. Charbonneau, M.R., O'Donnell, D., Blanton, L.V., Totten, S.M., Davis, J.C.C., Barratt, M.J., Cheng, J.,
 Guruge, J., Talcott, M., Bain, J.R., et al. (2016). Sialylated Milk Oligosaccharides Promote
 Microbiota-Dependent Growth in Models of Infant Undernutrition. Cell *164*, 859–871.
- Mank, M., Hauner, H., Heck, A.J.R., and Stahl, B. (2020). Targeted LC-ESI-MS2 characterization of
 human milk oligosaccharide diversity at 6 to 16 weeks post-partum reveals clear staging effects
 and distinctive milk groups. Anal Bioanal Chem *412*, 6887–6907.
- 32. Castanys-Muñoz, E., Martin, M.J., and Prieto, P.A. (2013). 2'-fucosyllactose: an abundant,
 genetically determined soluble glycan present in human milk. Nutr Rev 71, 773–789.

- Blank, D., Dotz, V., Geyer, R., and Kunz, C. (2012). Human milk oligosaccharides and Lewis blood
 group: individual high-throughput sample profiling to enhance conclusions from functional studies.
 Adv Nutr *3*, 440S-9S.
- Schneider, M., Al-Shareffi, E., and Haltiwanger, R.S. (2017). Biological functions of fucose in
 mammals. Glycobiology *27*, 601–618.
- 93835.Cooling, L. (2015). Blood groups in infection and host susceptibility. Clinical Microbiology Reviews93928.
- 36. Tong, M., McHardy, I., Ruegger, P., Goudarzi, M., Kashyap, P.C., Haritunians, T., Li, X., Graeber,
 T.G., Schwager, E., Huttenhower, C., et al. (2014). Reprograming of gut microbiome energy
 metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J *8*, 2193–2206.
- Rausch, P., Rehman, A., Künzel, S., Häsler, R., Ott, S.J., Schreiber, S., Rosenstiel, P., Franke, A., and
 Baines, J.F. (2011). Colonic mucosa-associated microbiota is influenced by an interaction of crohn
 disease and FUT2 (Secretor) genotype. Proceedings of the National Academy of Sciences of the
 United States of America *108*.
- 38. Gampa, A., Engen, P.A., Shobar, R., and Mutlu, E.A. (2017). Relationships between gastrointestinal
 microbiota and blood group antigens. Physiol Genomics *49*, 473–483.
- Wacklin, P., Mäkivuokko, H., Alakulppi, N., Nikkilä, J., Tenkanen, H., Räbinä, J., Partanen, J., Aranko,
 K., and Mättö, J. (2011). Secretor genotype (FUT2 gene) is strongly associated with the
 composition of bifidobacteria in the human intestine. PLoS ONE *6*, e20113.
- 40. Rühlemann, M.C., Hermes, B.M., Bang, C., Doms, S., Moitinho-Silva, L., Thingholm, L.B., Frost, F.,
 Degenhardt, F., Wittig, M., Kässens, J., et al. (2021). Genome-wide association study in 8,956
 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat Genet
 53, 147–155.
- 956 41. Christensen, L., Vuholm, S., Roager, H.M., Nielsen, D.S., Krych, L., Kristensen, M., Astrup, A., and
 957 Hjorth, M.F. (2019). Prevotella Abundance Predicts Weight Loss Success in Healthy, Overweight
 958 Adults Consuming a Whole-Grain Diet Ad Libitum: A Post Hoc Analysis of a 6-Wk Randomized
 959 Controlled Trial. J Nutr 149, 2174–2181.
- 42. Eriksen, A.K., Brunius, C., Mazidi, M., Hellström, P.M., Risérus, U., Iversen, K.N., Fristedt, R., Sun, L.,
 Huang, Y., Nørskov, N.P., et al. (2020). Effects of whole-grain wheat, rye, and lignan
 supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized
 crossover trial. Am J Clin Nutr *111*, 864–876. 10.1093/ajcn/nqaa026.
- 964 43. Shin, J.-H., Jung, S., Kim, S.-A., Kang, M.-S., Kim, M.-S., Joung, H., Hwang, G.-S., and Shin, D.-M.
 965 (2019). Differential Effects of Typical Korean Versus American-Style Diets on Gut Microbial
 966 Composition and Metabolic Profile in Healthy Overweight Koreans: A Randomized Crossover Trial.
 967 Nutrients *11*, E2450.
- 44. Hjorth, M.F., Roager, H.M., Larsen, T.M., Poulsen, S.K., Licht, T.R., Bahl, M.I., Zohar, Y., and Astrup,
 A. (2018). Pre-treatment microbial Prevotella-to-Bacteroides ratio, determines body fat loss
 success during a 6-month randomized controlled diet intervention. Int J Obes (Lond) 42, 580–583.

- 45. Li, Y., Wang, D.D., Satija, A., Ivey, K.L., Li, J., Wilkinson, J.E., Li, R., Baden, M., Chan, A.T.,
 Huttenhower, C., et al. (2021). Plant-Based Diet Index and Metabolic Risk in Men: Exploring the
 Role of the Gut Microbiome. J Nutr 151, 2780–2789.
- 46. Li, J., Li, Y., Ivey, K.L., Wang, D.D., Wilkinson, J.E., Franke, A., Lee, K.H., Chan, A., Huttenhower, C.,
 Hu, F.B., et al. (2022). Interplay between diet and gut microbiome, and circulating concentrations
 of trimethylamine N-oxide: findings from a longitudinal cohort of US men. Gut *71*, 724–733.
- Wang, D.D., Nguyen, L.H., Li, Y., Yan, Y., Ma, W., Rinott, E., Ivey, K.L., Shai, I., Willett, W.C., Hu, F.B.,
 et al. (2021). The gut microbiome modulates the protective association between a Mediterranean
 diet and cardiometabolic disease risk. Nat Med *27*, 333–343.
- 48. Hughes, R.L., Arnold, C.D., Young, R.R., Ashorn, P., Maleta, K., Fan, Y.-M., Ashorn, U., Chaima, D.,
 Malamba-Banda, C., Kable, M.E., et al. (2020). Infant gut microbiota characteristics generally do
 not modify effects of lipid-based nutrient supplementation on growth or inflammation: secondary
 analysis of a randomized controlled trial in Malawi. Sci Rep *10*, 14861.
- Smith, M.I., Yatsunenko, T., Manary, M.J., Trehan, I., Mkakosya, R., Cheng, J., Kau, A.L., Rich, S.S.,
 Concannon, P., Mychaleckyj, J.C., et al. (2013). Gut microbiomes of Malawian twin pairs discordant
 for Kwashiorkor. Science *339*, 548–554.
- 50. Schwarzer, M., Makki, K., Storelli, G., Machuca-Gayet, I., Srutkova, D., Hermanova, P., Martino,
 M.E., Balmand, S., Hudcovic, T., Heddi, A., et al. (2016). Lactobacillus plantarum strain maintains
 growth of infant mice during chronic undernutrition. Science *351*, 854–857.
- Humphrey, J.H., Mbuya, M.N.N., Ntozini, R., Moulton, L.H., Stoltzfus, R.J., Tavengwa, N.V., Mutasa,
 K., Majo, F.D., Mutasa, B., Mangwadu, G., et al. (2019). Independent and combined effects of
 improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting
 and anaemia in rural Zimbabwe: a cluster-randomised trial. The Lancet Global Health 7, e132–
 e147.
- Beghini, F., McIver, L.J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A.,
 Manghi, P., Scholz, M., Thomas, A.M., et al. (2021). Integrating taxonomic, functional, and strainlevel profiling of diverse microbial communities with bioBakery 3. Elife *10*, e65088.
- 998 53. Wieder, C., Frainay, C., Poupin, N., Rodríguez-Mier, P., Vinson, F., Cooke, J., Lai, R.P., Bundy, J.G.,
 999 Jourdan, F., and Ebbels, T. (2021). Pathway analysis in metabolomics: Recommendations for the
 1000 use of over-representation analysis. PLoS Comput Biol *17*, e1009105.
- 1001 54. The Gene Ontology Consortium, Aleksander, S.A., Balhoff, J., Carbon, S., Cherry, J.M., Drabkin, H.J.,
 1002 Ebert, D., Feuermann, M., Gaudet, P., Harris, N.L., et al. (2023). The Gene Ontology knowledgebase
 1003 in 2023. Genetics *224*, iyad031.
- 100455.Drula, E., Garron, M.-L., Dogan, S., Lombard, V., Henrissat, B., and Terrapon, N. (2022). The1005carbohydrate-active enzyme database: functions and literature. Nucleic Acids Res 50, D571–D577.
- Saier, M.H., Reddy, V.S., Moreno-Hagelsieb, G., Hendargo, K.J., Zhang, Y., Iddamsetty, V., Lam,
 K.J.K., Tian, N., Russum, S., Wang, J., et al. (2021). The Transporter Classification Database (TCDB):
 2021 update. Nucleic Acids Res *49*, D461–D467.

- 1009 57. Caspi, R., Billington, R., Fulcher, C.A., Keseler, I.M., Kothari, A., Krummenacker, M., Latendresse,
 1010 M., Midford, P.E., Ong, Q., Ong, W.K., et al. (2018). The MetaCyc database of metabolic pathways
 1011 and enzymes. Nucleic Acids Research *46*, D633–D639.
- 1012 58. Ye, Y., and Doak, T.G. (2009). A parsimony approach to biological pathway
 1013 reconstruction/inference for genomes and metagenomes. PLoS Comput Biol 5, e1000465.
- 1014 59. Bazanella, M., Maier, T.V., Clavel, T., Lagkouvardos, I., Lucio, M., Maldonado-Gòmez, M.X., Autran,
 1015 C., Walter, J., Bode, L., Schmitt-Kopplin, P., et al. (2017). Randomized controlled trial on the impact
 1016 of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and
 1017 metabolome. American Journal of Clinical Nutrition *106*, 1274–1286.
- 1018 60. Davenport, E.R., Cusanovich, D.A., Michelini, K., Barreiro, L.B., Ober, C., and Gilad, Y. (2015).
 1019 Genome-wide association studies of the human gut microbiota. PLoS ONE *10*.
 1020 10.1371/journal.pone.0140301.
- 1021 61. Turpin, W., Bedrani, L., Espin-Garcia, O., Xu, W., Silverberg, M.S., Smith, M.I., Guttman, D.S.,
 1022 Griffiths, A., Moayyedi, P., Panaccione, R., et al. (2018). FUT2 genotype and secretory status are
 1023 not associated with fecal microbial composition and inferred function in healthy subjects. Gut
 1024 Microbes 9.
- Bell, A., and Juge, N. (2021). Mucosal glycan degradation of the host by the gut microbiota.
 Glycobiology *31*, 691–696.
- 1027 63. Colston, J.M., Taniuchi, M., Ahmed, T., Ferdousi, T., Kabir, F., Mduma, E., Nshama, R., Iqbal, N.T.,
 1028 Haque, R., Ahmed, T., et al. (2022). Intestinal Colonization With Bifidobacterium longum
 1029 Subspecies Is Associated With Length at Birth, Exclusive Breastfeeding, and Decreased Risk of
 1030 Enteric Virus Infections, but Not With Histo-Blood Group Antigens, Oral Vaccine Response or Later
 1031 Growth in Three Birth Cohorts. Front Pediatr *10*, 804798.
- 1032 64. Robertson, R.C., Edens, T.J., Carr, L., Mutasa, K., Gough, E.K., Evans, C., Geum, H.M., Baharmand, I.,
 1033 Gill, S.K., Ntozini, R., et al. (2023). The gut microbiome and early-life growth in a population with
 1034 high prevalence of stunting. Nat Commun *14*, 654.
- Stewart, C.J., Ajami, N.J., O'Brien, J.L., Hutchinson, D.S., Smith, D.P., Wong, M.C., Ross, M.C., Lloyd,
 R.E., Doddapaneni, H.V., Metcalf, G.A., et al. (2018). Temporal development of the gut microbiome
 in early childhood from the TEDDY study. Nature *562*, 583–588.
- 1038 66. Yatsunenko, T., Rey, F.E., Manary, M.J., Trehan, I., Dominguez-Bello, M.G., Contreras, M., Magris,
 1039 M., Hidalgo, G., Baldassano, R.N., Anokhin, A.P., et al. (2012). Human gut microbiome viewed
 1040 across age and geography. Nature 486, 222–228.
- 104167.Marcobal, A., and Sonnenburg, J.L. (2012). Human milk oligosaccharide consumption by intestinal1042microbiota: Human milk oligosaccharide consumption. Clinical Microbiology and Infection 18, 12–104315.
- Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H.,
 Zhong, H., et al. (2015). Dynamics and stabilization of the human gut microbiome during the first
 year of life. Cell Host and Microbe *17*, 690–703. 10.1016/j.chom.2015.04.004.

- 104769.Collado, M.C., Cernada, M., Baüerl, C., Vento, M., and Pérez-Martínez, G. (2012). Microbial ecology1048and host-microbiota interactions during early life stages. Gut Microbes 3, 352–365.
- 1049 70. Matamoros, S., Gras-Leguen, C., Vacon, F.L., Potel, G., and Cochetiere, M.-F. de L. (2013).
 1050 Development of intestinal microbiota in infants and its impact on health. Trends in Microbiology 21, 167–173.
- 1052 71. Laursen, M.F. (2021). Gut Microbiota Development: Influence of Diet from Infancy to Toddlerhood.
 1053 Annals of Nutrition and Metabolism.
- 1054 72. Lewis, Z.T., Totten, S.M., Smilowitz, J.T., Popovic, M., Parker, E., Lemay, D.G., Van Tassell, M.L.,
 1055 Miller, M.J., Jin, Y.-S., German, J.B., et al. (2015). Maternal fucosyltransferase 2 status affects the
 1056 gut bifidobacterial communities of breastfed infants. Microbiome *3*, 13.
- 1057 73. Ojima, M.N., Jiang, L., Arzamasov, A.A., Yoshida, K., Odamaki, T., Xiao, J., Nakajima, A., Kitaoka, M.,
 1058 Hirose, J., Urashima, T., et al. (2022). Priority effects shape the structure of infant-type
 1059 Bifidobacterium communities on human milk oligosaccharides. ISME J *16*, 2265–2279.
- 1060 74. Li, M., Zhou, X., Stanton, C., Ross, R.P., Zhao, J., Zhang, H., Yang, B., and Chen, W. (2021).
 1061 Comparative Genomics Analyses Reveal the Differences between B. longum subsp. infantis and B.
 1062 longum subsp. longum in Carbohydrate Utilisation, CRISPR-Cas Systems and Bacteriocin Operons.
 1063 Microorganisms 9, 1713.
- 1064 75. Gotoh, A., Katoh, T., Sakanaka, M., Ling, Y., Yamada, C., Asakuma, S., Urashima, T., Tomabechi, Y.,
 1065 Katayama-Ikegami, A., Kurihara, S., et al. (2018). Sharing of human milk oligosaccharides
 1066 degradants within bifidobacterial communities in faecal cultures supplemented with
 1067 Bifidobacterium bifidum. Scientific Reports *8*, 13958.
- Sakanaka, M., Gotoh, A., Yoshida, K., Odamaki, T., Koguchi, H., Xiao, J.-Z., Kitaoka, M., and
 Katayama, T. (2019). Varied Pathways of Infant Gut-Associated Bifidobacterium to Assimilate
 Human Milk Oligosaccharides: Prevalence of the Gene Set and Its Correlation with BifidobacteriaRich Microbiota Formation. Nutrients *12*, 71. 10.3390/nu12010071.
- 1072 77. Garrido, D., Ruiz-Moyano, S., Lemay, D.G., Sela, D.A., German, J.B., and Mills, D.A. (2015).
 1073 Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of 1074 infant gut-associated bifidobacteria. Sci Rep *5*, 13517.
- 1075 78. Garrido, D., Ruiz-Moyano, S., Kirmiz, N., Davis, J.C., Totten, S.M., Lemay, D.G., Ugalde, J.A.,
 1076 German, J.B., Lebrilla, C.B., and Mills, D.A. (2016). A novel gene cluster allows preferential
 1077 utilization of fucosylated milk oligosaccharides in Bifidobacterium longum subsp. longum SC596.
 1078 Sci Rep *6*, 35045.
- 1079 79. Vatanen, T., Ang, Q.Y., Siegwald, L., Sarker, S.A., Le Roy, C.I., Duboux, S., Delannoy-Bruno, O.,
 1080 Ngom-Bru, C., Boulangé, C.L., Stražar, M., et al. (2022). A distinct clade of Bifidobacterium longum
 1081 in the gut of Bangladeshi children thrives during weaning. Cell *185*, 4280-4297.e12.
- 1082 80. Sela, D.A., Chapman, J., Adeuya, A., Kim, J.H., Chen, F., Whitehead, T.R., Lapidus, A., Rokhsar, D.S.,
 1083 Lebrilla, C.B., German, J.B., et al. (2008). The genome sequence of Bifidobacterium longum subsp.

- infantis reveals adaptations for milk utilization within the infant microbiome. Proceedings of the
 National Academy of Sciences *105*, 18964–18969.
- 108681.Thomson, P., Medina, D.A., and Garrido, D. (2018). Human milk oligosaccharides and infant gut1087bifidobacteria: Molecular strategies for their utilization. Food Microbiology 75, 37–46.
- LoCascio, R.G., Desai, P., Sela, D.A., Weimer, B., and Mills, D.A. (2010). Broad conservation of milk
 utilization genes in Bifidobacterium longum subsp. infantis as revealed by comparative genomic
 hybridization. Appl Environ Microbiol *76*, 7373–7381.
- 109183.Fushinobu, S., and Abou Hachem, M. (2021). Structure and evolution of the bifidobacterial1092carbohydrate metabolism proteins and enzymes. Biochem Soc Trans 49, 563–578.
- 1093 84. Wei, X., Guo, Y., Shao, C., Sun, Z., Zhurina, D., Liu, D., Liu, W., Zou, D., Jiang, Z., Wang, X., et al.
 1094 (2012). Fructose Uptake in Bifidobacterium longum NCC2705 Is Mediated by an ATP-binding
 1095 Cassette Transporter. Journal of Biological Chemistry 287, 357–367. 10.1074/jbc.M111.266213.
- 109685.Johnstone, T.C., and Nolan, E.M. (2015). Beyond Iron: Non-Classical Biological Functions of1097Bacterial Siderophores. Dalton Trans 44, 6320–6339.
- 1098 86. Vazquez-Gutierrez, P., Lacroix, C., Jaeggi, T., Zeder, C., Zimmerman, M.B., and Chassard, C. (2015).
 1099 Bifidobacteria strains isolated from stools of iron deficient infants can efficiently sequester iron.
 1100 BMC Microbiol 15, 3.
- 1101 87. Vazquez-Gutierrez, P., de Wouters, T., Werder, J., Chassard, C., and Lacroix, C. (2016). High Iron 1102 Sequestrating Bifidobacteria Inhibit Enteropathogen Growth and Adhesion to Intestinal Epithelial
 1103 Cells In vitro. Front Microbiol 7, 1480.
- 110488.Gibson, G. r., and Wang, X. (1994). Regulatory effects of bifidobacteria on the growth of other1105colonic bacteria. Journal of Applied Bacteriology 77, 412–420.
- Arimond, M., Zeilani, M., Jungjohann, S., Brown, K.H., Ashorn, P., Allen, L.H., and Dewey, K.G.
 (2015). Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS)
 Project. Matern Child Nutr 11, 31–61.
- 90. Beal, T., White, J.M., Arsenault, J.E., Okronipa, H., Hinnouho, G.-M., Murira, Z., Torlesse, H., and
 Garg, A. (2021). Micronutrient gaps during the complementary feeding period in South Asia: A
 Comprehensive Nutrient Gap Assessment. Nutr Rev *79*, 26–34.
- 111391.White, J.M., Beal, T., Arsenault, J.E., Okronipa, H., Hinnouho, G.-M., Chimanya, K., Matji, J., and1114Garg, A. (2021). Micronutrient gaps during the complementary feeding period in 6 countries in1115Eastern and Southern Africa: a Comprehensive Nutrient Gap Assessment. Nutr Rev 79, 16–25.
- Park, J.J.H., Harari, O., Siden, E., Dron, L., Zannat, N.-E., Singer, J., Lester, R.T., Thorlund, K., and
 Mills, E.J. (2020). Interventions to improve linear growth during complementary feeding period for
 children aged 6-24 months living in low- and middle-income countries: a systematic review and
 network meta-analysis [version 2; peer review: 3 approved]. *3*, 1660.

- 1120 93. Imdad, A., and Bhutta, Z.A. (2011). Effect of preventive zinc supplementation on linear growth in
 1121 children under 5 years of age in developing countries: a meta-analysis of studies for input to the
 1122 lives saved tool. BMC Public Health *11*, S22.
- 94. Ashorn, P., Alho, L., Ashorn, U., Cheung, Y.B., Dewey, K.G., Gondwe, A., Harjunmaa, U., Lartey, A.,
 Phiri, N., Phiri, T.E., et al. (2015). Supplementation of Maternal Diets during Pregnancy and for 6
 Months Postpartum and Infant Diets Thereafter with Small-Quantity Lipid-Based Nutrient
 Supplements Does Not Promote Child Growth by 18 Months of Age in Rural Malawi: A Randomized
 Controlled Trial. J Nutr 145, 1345–1353. 10.3945/jn.114.207225.
- 1128 95. Abellan-Schneyder, I., Matchado, M.S., Reitmeier, S., Sommer, A., Sewald, Z., Baumbach, J., List,
 1129 M., and Neuhaus, K. (2021). Primer, Pipelines, Parameters: Issues in 16S rRNA Gene Sequencing.
 1130 mSphere 6, e01202-20.
- Paganini, D., Uyoga, M.A., Kortman, G.A.M., Boekhorst, J., Schneeberger, S., Karanja, S., Hennet, T.,
 and Zimmermann, M.B. (2019). Maternal Human Milk Oligosaccharide Profile Modulates the
 Impact of an Intervention with Iron and Galacto-Oligosaccharides in Kenyan Infants. Nutrients *11*,
 2596.
- Schwartz, D.J., Langdon, A., Sun, X., Langendorf, C., Berthé, F., Grais, R.F., Trehan, I., Isanaka, S.,
 and Dantas, G. (2023). Effect of amoxicillin on the gut microbiome of children with severe acute
 malnutrition in Madarounfa, Niger: a retrospective metagenomic analysis of a placebo-controlled
 trial. The Lancet Microbe 4, e931–e942.
- 1139 98. Ruiz, L., Flórez, A.B., Sánchez, B., Moreno-Muñoz, J.A., Rodriguez-Palmero, M., Jiménez, J., Gavilán,
 1140 C.G. de los R., Gueimonde, M., Ruas-Madiedo, P., and Margolles, A. (2020). Bifidobacterium
 1141 longum subsp. infantis CECT7210 (B. infantis IM-1[®]) Displays In Vitro Activity against Some
 1142 Intestinal Pathogens. Nutrients *12*, 3259.
- 1143 99. Henrick, B.M., Rodriguez, L., Lakshmikanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., Wang,
 1144 J., Mikes, J., Tan, Z., et al. (2021). Bifidobacteria-mediated immune system imprinting early in life.
 1145 Cell 184, 3884-3898.e11.
- 100. Dai, D.L.Y., Petersen, C., Hoskinson, C., Del Bel, K.L., Becker, A.B., Moraes, T.J., Mandhane, P.J.,
 Finlay, B.B., Simons, E., Kozyrskyj, A.L., et al. (2023). Breastfeeding enrichment of B. longum subsp.
 infantis mitigates the effect of antibiotics on the microbiota and childhood asthma risk. Med *4*, 92112.e5.
- 101. Barratt, M.J., Nuzhat, S., Ahsan, K., Frese, S.A., Arzamasov, A.A., Sarker, S.A., Islam, M.M., Palit, P.,
 1151 Islam, M.R., Hibberd, M.C., et al. (2022). Bifidobacterium infantis treatment promotes weight gain
 1152 in Bangladeshi infants with severe acute malnutrition. Sci Transl Med *14*, eabk1107.
- 1153 102. Nuzhat, S., Hasan, S.M.T., Palit, P., Islam, M.R., Mahfuz, M., Islam, M.M., Alam, M.A., Flannery, R.L.,
 1154 Kyle, D.J., Sarker, S.A., et al. (2023). Effects of probiotic and synbiotic supplementation on ponderal
 1155 and linear growth in severely malnourished young infants in a randomized clinical trial. Sci Rep *13*,
 1156 1845.
- 103. Humphrey, J.H., Jones, A.D., Manges, A., Mangwadu, G., Maluccio, J.A., Mbuya, M.N.N., Moulton,
 L.H., Ntozini, R., Prendergast, A.J., Stoltzfus, R.J., et al. (2015). The sanitation hygiene infant

- 1159 nutrition efficacy (SHINE) Trial: Rationale, design, and methods. Clinical Infectious Diseases *61*,
 1160 S685-702.
- 104. Chasekwa, B., Maluccio, J.A., Ntozini, R., Moulton, L.H., Wu, F., Smith, L.E., Matare, C.R., Stoltzfus,
 R.J., Mbuya, M.N.N., Tielsch, J.M., et al. (2018). Measuring wealth in rural communities: Lessons
 from the sanitation, hygiene, infant nutrition efficacy (SHINE) trial. PLoS ONE *13*, 1–19.
- 105. Maxwell, D., Watkins, B., Wheeler, R., and Collins, G. (2003). The Coping Strategy Index: a tool for
 rapid measurement of household food security and the impact of food aid programs in
 humanitarian emergencies. (CARE and WFP).
- 106. E.K, G., L.H, M., K, M., R, N., R.J, S., F.D, M., L.E, S., G, P., N, G., M, J., et al. (2020). Effects of
 improved water, sanitation, and hygiene and improved complementary feeding on environmental
 enteric dysfunction in children in rural Zimbabwe: A cluster-randomized controlled trial. PLoS
 Neglected Tropical Diseases *14*, e0007963.
- 107. Mutasa, K., Ntozini, R., Mbuya, M.N.N., Rukobo, S., Govha, M., Majo, F.D., Tavengwa, N., Smith,
 L.E., Caulfield, L., Swann, J.R., et al. (2021). Biomarkers of environmental enteric dysfunction are
 not consistently associated with linear growth velocity in rural Zimbabwean infants. The American
 journal of clinical nutrition *113*.
- 1175 108. Colston, J.M., Francois, R., Pisanic, N., Yori, P.P., Mccormick, B.J.J., Olortegui, M.P., Gazi, M.A.,
 1176 Svensen, E., Ahmed, M.M.M., Mduma, E., et al. (2019). Effects of Child and Maternal Histo-Blood
 1177 Group Antigen Status on Symptomatic and Asymptomatic Enteric Infections in Early Childhood.
 1178 Journal of Infectious Diseases 220, 151–162.
- 1179 109. Legendre, P., and Anderson, M.J. (1999). Distance-Based Redundancy Analysis: Testing
 1180 Multispecies Responses in Multifactorial Ecological Experiments. Ecological Monographs 69, 1–24.
- 1181110. Anderson, M.J. (2001). A new method for non-parametric multivariate analysis of variance. Austral1182Ecology 26, 32–46.
- 1183 111. VanderWeele, T.J. (2012). Sample Size and Power Calculations for Additive Interactions. Epidemiol
 1184 Methods 1, 159–188.
- 1185 112. Naimi, A.I., and Whitcomb, B.W. (2020). Estimating Risk Ratios and Risk Differences Using
 1186 Regression. Am J Epidemiol *189*, 508–510.
- 113. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
 Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B
 (Methodological) 57, 289–300.
- 114. Scholz, M., Ward, D.V., Pasolli, E., Tolio, T., Zolfo, M., Asnicar, F., Truong, D.T., Tett, A., Morrow,
 A.L., and Segata, N. (2016). Strain-level microbial epidemiology and population genomics from
 shotgun metagenomics. Nature Methods *13*, 435–438.
- 1193 115. Murtagh, F., and Legendre, P. (2014). Ward's Hierarchical Agglomerative Clustering Method:
 1194 Which Algorithms Implement Ward's Criterion? Journal of Classification *31*, 274–295.

- 1195 116. Chen, E.Z., and Li, H. (2016). A two-part mixed-effects model for analyzing longitudinal microbiome 1196 compositional data. In Bioinformatics, pp. 2611–2617. 10.1093/bioinformatics/btw308.
- 1197 117. Kosmidis, I., Kenne Pagui, E.C., and Sartori, N. (2020). Mean and median bias reduction in
 generalized linear models. Stat Comput *30*, 43–59.
- 1199 118. Mansournia, M.A., Geroldinger, A., Greenland, S., and Heinze, G. (2018). Separation in Logistic
 Regression: Causes, Consequences, and Control. Am J Epidemiol *187*, 864–870.
- 119. Dixon, P. (2003). VEGAN, a package of R functions for community ecology. Journal of Vegetation
 Science 14, 927–930.
- 1203 120. Stasinopoulos, D.M., and Rigby, R.A. (2007). Generalized additive models for location scale and 1204 shape (GAMLSS) in R. Journal of Statistical Software *23*, 1–46. 10.18637/jss.v023.i07.
- 1205

no IYCF IYCF





B. longum Rel. Ab. — Low — High



Component 1

Component 2



B Pathway type

Glycan Pathways

- Fatty Acid and Lipid Biosynthesis
- Secondary Metabolite Biosynthesis
- Other Biosynthesis
- Generation of Precursor Metabolites and Energy























infantis vs longum infantis vs suis

B. longum strain





MetaCyc Pathway

- Both - Infant only - Mother only - None





Infant Age (months)

Probability of Detection

